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Nonspecific Inhibition of Encephalomyocarditis Virus 
Replication by Immune Interferon Released from Unstimu­
lated Cells of Mice Sensitized with Nonviable Mycobac­
terium tuberculosis (102 pp.) 
Director: Donald L. Lodmell 
Inhibition of encephalomyocarditis virus (EMCV) 
replication was demonstrated in mouse embryo fibroblasts 
(MEF) monolayers by incubating peritoneal cells (PC) 
from mice sensitized intraperitoneally (i.p.) or intra-
veneously (i.v.) 2-10 weeks previously with 50-500 ug 
of nonviable Mycobacterium tuberculosis, strain Jamaica, 
suspended in an oil-in-saline emulsion. PC from myco-
bacteria-sensitized mice at a PC-to-MEF ratio of 20 
inhibited viral replication by >. 1-2 log^o as compared 
to PC from normal mice when incubated on MEF monolayers 
infected 2-8 h previously with EMCV. Inhibition of 
EMCV replication was first detected 12 h post-infection 
and was not due to depletion of culture nutrients, 
changes in pH, nor temperature dependence. In addition, 
EMCV was prevented from spreading to uninfected mono­
layer cells, but viral inhibition was not due to cyto­
toxicity of MEF by PC. Supernatant fluids prepared 
from PC cultures of mycobacteria-sensitized mice in­
hibited viral replication. The antiviral activity in 
supernatant fluids elicited without mycobacterial 
antigen stimulation was labile to acid, heat and trypsin, 
and was active in mouse cells against several RNA or 
DNA viruses. Furthermore, the antiviral activity of 
supernatant fluids was neutralized by rabbit anti-type 
II mouse interferon, but not anti-type I mouse interferon. 
Thus, an immune type II mouse interferon released from 
unstimulated PC of mycobacteria-sensitized mice appears 
to be responsible for the inhibition of EMCV replication. 
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INTRODUCTION 
The importance of cell-mediated immunity (CMI) in viral 
infections is well documented (13»38,64). Individuals with 
agammaglobulinemia recover normally from most viral infec­
tions, yet those lacking in CMI do not (64). The mechanisms 
of protection in Civil are varied, but include two major 
types: specific responses elicited by antigens similiar to 
the infectious agent that ultimately provide protection 
against only that agent (7.20,22), and nonspecific responses 
elicited by agents which induce a state of resistance 
against a variety of phylogenetically diverse organisms (59). 
Several facultative intracellular bacterial species known 
to induce nonspecific CMI ard ivlycobacteria, especially 
Bacille Calmette-Guerin (BCG), Corynebacteria, Listeria, 
Brucella, and Salmonella, although chemical compounds such 
as pyran, polyinosinic acid-polycytidylic acid (poly (I)-
poly (G)) and thioglycollate also can elicit nonspecific 
CMI (30,42). The nonspecific CMI induced by facultative 
intracellular parasites appear to share several character­
istics: there is an association with delayed hypersensitiv­
ity, the acquired resistance cannot be passively transferred 
with serum, and there is an increase in host macrophage 
activity (43). In addition, immunological resistance in­
duced by facultative intracellular parasites can protect 
the host against neoplasms and a variety of organisms 
including bacteria, protozoa, and viruses (36,59). 
1 
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Because immunological resistance can be attained against 
unrelated organisms, it has been suggested that common 
mechanisms of immunity underlie all intracellular infectr-
ions (59)• 
Many investigations have been conducted on the non­
specific phase of CMI to determine its role in the immune 
response. One of the earliest studies was done by Mackaness 
et al. who used BCG to induce resistance to Listeria mono­
cytogenes and Salmonella typhimurium (6, 43). Six days 
after intravenous (i.v.) injection with live BCG, suseptible 
mice were highly resistant to i.v. challenge with virulent 
L. monocytogenes (6). Resistance was determined by the 
increased rate of clearance of L. monocytogenes from the 
blood, decreased numbers of challenge bacteria present 
in the liver and spleen and by the increased survival 
of mice. In another study, Sulitzeanu induced resistance 
"k° Brucella abortus following an intraperitoneal (i.p.) 
or i.v. challenge by the L.p. injection 7-14 days previous­
ly with either live or dead BCG (68). As in the previous 
study, resistance was associated with decreased numbers 
of the challenge bacteria in the liver and spleen. 
The nonspecific enhancement of resistance by BCG is 
not limited to bacteria. Civil et al. demonstrated enhanced 
resistance to Schistosoma mansoni, a multicellular helminth 
parasite, that was dependent on the dose, route, and time 
of administration of BCG, as well as the strain of mouse 
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used (10). Nonspecific Civil also was demonstrated in vivo 
and in vitro by Ruskin ejt al. with mice chronically infected 
with Toxoplasma (59). When animals were challenged with a 
lethal dose of Listeria, mortality decreased from 100 to 
and this resistance could not be passively transferred with 
sera to normal mice. Furthermore, monolayers of peritoneal 
cells (PC) removed from normal mice were destroyed when 
challenged with Listeria, whereas PC monolayers from 
Toxoplasma or Besnoitia-infected mice persisted. 
More recently, work with nonspecific Civil has been ex­
panded to include resistance to viral infections and 
tumors. In a study done by Starr et al., i.p. or intra­
dermal (i.d.) administration of live BCG to newborn mice 
6 days prior to challenge with herpes simplex virus (HSV), 
increased the survival time of the animals (66). Kirchner 
et al. also were able to induce resistance to HSV by the 
i.p. or i.v. injection of killed Corynebacterium parvum or 
Bordetella pertussis (33). In some instances, nonspecific 
resistance to infections has been demonstrated with cell 
walls or other fractions of the eliciting organisms (8, 32). 
One example of such a study was done by Kern e_t al. in 
which Bru-Pel, a cell wall preparation of Brucella abortus, 
injected i.p. induced significant protection in mice 
challenged i.p.with HSV type 2 (32); the protective effect 
of Bru-Pel was not detected if virus was given intranasally. 
Other investigators have studied antitumor as well as 
antiviral effects in nonspecifically mediated CMI (8, 11, 36). 
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In a study by Lamensans e_t al., it was determined that an 
i.p. injection of BCG 14 days prior to i.p. implantation 
of Leukemia-L 1210 cells significantly increased the mean 
survival time (MST) of mice (36). The same prophylactic 
treatment also increased the MST of mice challenged with 
Columbia SK virus. Studies conducted by Clark et al. 
noted similarities in resistance to babesiosis and tumor 
regression elicited by BCG infection (11). These similar­
ities included enhanced protection following an i.v. rather 
than subcutaneous (s.c.) injection of BCG, protection in 
thymectomized or splenectomized animals (as long as the 
spleen was removed prior to BCG administration) and mechan­
isms of protection that were resistant to radiation and 
cyclophosphamide, but not to cortisone. 
A number of immunological mechanisms have been associ­
ated with nonspecific enhancement of resistance (2, 35» 42). 
Many early studies noted an increased activity of the 
reticuloendothial system (Kj23) and it was postulated that 
activated macrophages were effective against many organisms, 
including those that were used to induce their elevated 
state of activity (42, 43). Activated macrophages were 
first described by Mackaness who noted th.-it they had an 
increased metabolism, enhanced phagocytic capability, high 
microbicidal activity and a distinctive morphology.(42, 55)» 
In addition, activated macrophages recently have been shown 
to possess a marked tumoricidal effect as well as an ability 
to inhibit viral replication (1, 3°). Furthermore Schleupner 
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et al.,utilizing the technique of chemiluminescence (GL), 
demonstrated that viral infections induce activated macro­
phages; PC from vaccinia virus (VV) or cytomegalovirus (CMV)-
infected animals emitted increased amounts of CL during 
phagocytosis of zymosan particles or yeasts as compared 
to PC from uninfected animals (61). CL is a technique 
which measures the amount of light emitted by phagocytic 
cells; the source of light is thought to involve interac­
tions of the ingested particles and oxidizing agents of 
the cells (H^Og* 02~. etc.) (9). Activated macrophages, 
because of their increased metabolism, have more oxidizing 
agents and thus emit increased amounts of CL (9» 61). 
Because more recent studies have indicated that macrophage 
activation is a varied phenomena, new criteria based on biochemi­
cal activity as well as differences in antitumor and anti­
viral activities (51) have been established to precisely 
define the mechanisms of activation (31). It has been 
established that 1) activated macrophages are derived from 
animals infected with BCG, Listeria, or other facultative: 
intracellular parasites, 2) stimulated or elicited macro­
phages are from animals injected with peptone, thioglycollate 
or chemical substances and 3) specifically conditioned 
macrophages are those that have been exposed Ln vitro to 
products of stimulated lymphocytes.(31)• 
Many studies have been undertaken to characterize the 
mechanism of macrophage activation, and in several instances, 
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there appears to be an interaction between two or more 
immunological cell types (25, 35)• Hadden has determined 
that sensitized lymphocytes, when restimulated with specific, 
antigen (Ag), produce macrophage mitogenic factor (MMF) 
which causes macrophages to proliferate in culture (25). 
Prostaglandin has been postulated to act as a negative 
feedback regulator of MMF function, although it was 
indicated that interferon or migration inhibitory factor 
(MIF) also could act in this capacity (25). 
The antiviral mechanisms of activated macrophages have 
been more thoroughly characterized. Increased phagocytosis 
of the virions or virus-infected cells (cytotoxicity) can 
occur, as well as inhibition of viral replication through 
the mechanism of compartmentalization (52, 55» 56, 64). 
Early investigations by Muyembe et al. concluded that mice 
injected i.p. v/ith Brucella abortus were resistant to Mengo 
virus infection by the same route because virus in the peri­
toneum was trapped by macrophages and thus did not reach 
the circulation (52). A similiar conclusion was reached 
by Spencer et al. who demonstrated that local (nasal) 
immunization with BCG elicited significantly better local 
CMI than did parenterally immunized animals, in 
contrast, parenterally immunized animals demonstrated better 
systemic immunity (64, 65). Mims and Gould described a 
compartmentalization-type phenomena in vitro in which a CMV 
infection was contained by broth-stimulated macrophages and 
thereby prevented from spreading to suseptible underlying 
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mouse embryo fibroblasts (MEF) monolayers (49). In this 
system, differences were noted between stimulated and normal 
macrophages by their ability to contain, control and inac­
tivate virus after phagocytosis, macrophages cytotoxic 
for virus-infected cells have been shown by Kaplan who 
demonstrated that pyran-stimulated macrophages were effective 
in halting tumor growth (30)» and by Probert who showed that 
unstimulated calf alveolar macrophages were cytotoxic and 
responsible for inhibition of parainfluenza-3 (PI-3) viral 
replication in calf kidney cells (54). In addition, Rodda 
et al. studied the inhibition of Semliki Forest Virus (SFV) 
replication in Vero cells by PC or spleen cells from normal 
mice or mice which had been infected with SFV (56). It was 
determined that cytotoxic macrophages were present one day 
after viral injection, peaked on days 2 and 3 and disappeared 
within a week. Specific immune responses in the form of 
sensitized-T cells and cytotoxic Ab then appeared (56). 
Thus, activated macrophages were functioning as early reg­
ulatory cells co-operating with other components of the 
immune system. This early regulation also was demonstrated 
by Kurland ejt al. who detected the release of a soluble 
mediator from thioglycollate-stimulated macrophages which 
caused B cell proliferation iri vitro (35). 
Activated macrophages, as well as T and B lymphocytes, 
have been demonstrated to release a number of immunological 
mediators, the most well studied of which is interferon 
(35, 44). This nonspecific antiviral mediator was discovered 
8 
in 1957 "by Isaacs and Lindenmann (3» 18), and on a molar 
basis it is one of the most active protein molecules 
known (18). There are two types of mouse interferon which 
are well characterized, although it is possible that others 
exist. Type I interferon, induced by nonspecific stimuli such 
as poly (I)-poly (C) or viruses, is heat labile and acid stable, 
whereas type II, immune or T interferon which is heat stable 
and acid labile is produced by sensitized cells in response 
to a specific Ag (18). Physically, interferon molecules 
which are quite heterogeneous also differ in their biological 
properties depending on their cellular source and mode of 
induction. Type I interferon generally is associated with 
macrophages and nonspecific stimuli, whereas lymphocytes 
produce immune type II interferon after antigenic stimulation 
of sensitized cells (44). All interferons are nondialyzable, 
sensitive to trypsin, and are usually species, but not viral 
specific (3)« Their molecular weights have been reported 
to range from 18,000 to 100,000 daltons which reflect the 
heterogenicity of the molecules involved (5). 
Interferons have been associated with nonspecific viral 
inhibition in many studies including the one conducted by 
Kern e_t al. (32). In this system, an ether extract of 
Brucella abortus (Bru-Pel) when injected i.p. 6-12 h before 
encephalomyocarditis virus (EMCV) or HSV, induced high levels 
of type I interferon. In addition, Bru-Pel when injected 
7-14 days before virus challenge was shown to activate the 
RES which also protected mice. Thus, interferon was postulated 
9 
to play an early regulatory role in viral infections. 
Similiar results have been reported by Virelizier ejt al. 
who showed that type I interferon was important in the ini­
tial resistance to mouse hepatitis virus type 3. "but it was 
not the sole immunological response associated with pro­
tection of infected animals (70). The interferon was 
capable, however, of containing the viral infection until 
other parameters of the immune system, such as antiviral 
activated macrophages could respond. In other studies, 
Suntharasamai and Rytel (69) demonstrated that an i.p. 
injection of Eperythrozoon coccoides, a blood parasite, 
induced high levels of interferon. The production of inter­
feron was biphasic in that it peaked on day 1, dropped in 
titer, and then peaked again on day 4. Its effect on para­
sitemia was transient in that there was an initial delay in 
replication of the blood parasite followed by an enhancement 
of replication. In contrast, E. coccoides has been shown 
to protect mice against SFV challenge and this protection 
was thought to be mediated through type I interferon. Hirt 
et al. studied another system in which spleen cells from 
mice injected with C. parvum were found to produce high 
levels of immune interferon with and without stimulation 
of sensitized cells by the addition of corynebacteria to the 
culture system (26). Immune interferon was identified as 
the mediator with physical characterization studies and by 
its inhibition of viral replication in pretreated target 
cells. The presence of interferon also was detected in an 
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in vitro study by Lodmell and Notkins with HSV-infected 
primary rabbit kidney (PRK) cells (38). Leukocytes removed 
from rabbits previously stimulated with HSV or complete 
Freund's adjuvant (CFA) inhibited viral replication in 
vitro after incubation of the effector cells with specific 
Ag. A mediator present in supernatant fluids harvested 
from the stimulated leukocytes also inhibited viral repli­
cation, and based on biological characteristics and behavior 
of the mediator, it was identified as interferon. Gresser 
conducted an in vivo study in which anti-mouse type I 
interferon was administered to mice prior to Eiv'iCV challenge 
(24). The mice which had been given the antisera plus 
virus died of an overwhelming systemic disease in 3 days 
rather than at 5 days of a central nervous system (CMS) dis­
order, which occurs in mice that had received only the virus 
inoculum (24). It was concluded that interferon was impor­
tant in limiting virus replication during the course of 
disease by its regulation of the number of virions which 
enter the circulation and target organs (1, 24). 
Interferons not only act as antiviral mediators, but 
they also interact with the immune system and are known to 
cause changes in CMI responses (13)• Type I interferon 
prolongs skin graft survival across Hr-2 barriers, abolishes 
delayed-type hypersensitivity (DTH) reactions, decreases 
development of bone marrow derived cells and causes changes 
in lymphocyte cell surfaces (13)• In addition, Manejias 
conducted a study in v/hich he postulated a direct correlation 
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between the production of type I interferon and an increased 
ability of PC from mice infected with Newcastle Disease 
Virus (NDV) to phagocytize Ab-coated erythrocytes (45). 
The role of type II interferon is less clear but it is 
thought to control and to regulate immune functions during 
viral infections (13)• 
Biochemically, the antiviral mechanism of interferon 
activity has been analysed by a number of investigators. 
During the early stages of virus infection, some event, 
probably the presence of foreign virion nucleic acid, 
derepresses a cellular gene which results in interferon 
production (3)» The interferon does not inhibit viral 
replication but it is secreted into the extracellular fluid 
where it reacts with membranes of surrounding cells to de-
repress a second gene within the cells. This derepression 
results in the production of intracellular antiviral proteins 
which inhibit synthesis of essential viral proteins or 
mRNA (3, 46). Thus, this mechanism explains the nonspecific, 
nature of interferon molecules; a broad range of viruses 
can stimulate interferons that are specific for the animal 
cell type in which they are induced (3). 
Antiviral mediators that cannot be classified as 
known interferons have been detected (34, 47, 58)* Kirchner 
showed that spleen cells from C. parvum-sensitized mice 
produced a factor which inhibited HSV replication in MSF 
monolayers, yet he was not able to conclusively identify 
this substance as any of the known interferons (34). 
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A similiar mediator was described by Rouse et al. who de­
tected an antiviral substance in supernatant fluids of 
bovine polymorphonuclear (PMW) leukocytes cultures after 
exposure to H3V (5^). This substance was shown to be active 
in heterologous cell lines in addition to being intermediate 
in its acid stability. Using these criteria, it was identi­
fied as something other than a known bovine interferon. 
Antiviral activity also was detected in human and bovine 
milk by Matthews jet al. and its behavior was unlike known 
interferon preparations (47). In contrast to interferon, 
preincubation of monolayer cells with the milk did not inhi­
bit viral replication; the milk had to be added to the mono­
layers concurrently with the virus. From these results, 
it was postulated that the antiviral substance interferred 
with the attachment or penetration of the virus which is 
unlike the known antiviral mechanisms of classical inter­
feron (3. 46, 47). 
As mentioned previously, interferon not only inhibits 
viral replication, but has a number of effects on other 
immunological parameters. For example, Djeu et al. stated 
that type I interferon augmented natural killer (NK) cell 
activity against tumor cells (14, 15)» and Santoli ejt al. 
reached the same conclusion in their study of measles-infects 
ed human fibroblasts (60). Recently, NK cells have been 
described as lymphocytes which lack T or B cell markers, 
are sensitive to trypsin and are innately cytotoxic (2, 60). 
This cytotoxicity can nonspecifically halt viral replication 
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by destroying target cells that are necessary for viral 
replication. NK cells are not the only cells which are 
cytotoxic; activated macrophages, killer (K) cells, T lymph­
ocytes and their soluble lymphokines have been shown to 
have similiar activities (7, 19» 22, 56). In work by 
Fujimiya e^t al. , it was concluded that the NK cell in blood 
v from infected patients was responsible for the direct lympho-
cytotoxicity observed against HSV-infected cells (19)• This 
cytotoxicity was demonstrated by incorporation of ̂ Icr into 
target cells and measuring the amount of radioactivity 
released after incubation with the lymphocytes (57). In 
Fujimiya's system, the effector cell lacked classical T cell 
markers and was sensitive to trypsinization. NK cells also 
are cytotoxic to tumor cells as well as virus-infected 
cells (2, 74). NK tumor cell cytotoxicity was studied by 
Wolfe et al. who concluded that the NK was the effector 
cell from PC of BCG-infected mice because it was nonadherent., 
nonphagocytic, and lacked the theta Ag (74); furthermore 
the activity of the NK cell was trypsin sensitive and 
labile at 37°C. 
Another type of nonphagocytic, nonadherent, non T or B 
cell has been identified as a cytotoxic effector. This 
killer (K) cell, which functions only in the presence of 
antibody (Ab), is responsible for an immunological mechanism 
of resistance termed Ab-dependent-cell-mediated cytotoxicity 
(ADCC) (41). The K cell is similiar in physical character­
istics to the NK cell, but requires IgG specific for the 
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virus to function (4l). Greenberg studied ADCC with non­
adherent, nonphagocytic cells from individuals who had been 
exposed to influenza virus and found that destruction of 
influenza-infected cells occured only in the presence of 
viral Ab (22). When Ab was removed, the cytotoxicity was 
greatly reduced. In a similiar study by Galama, the K 
cell was responsible for ADCC against measles-infected 
target cells (20); ADCC does not appear, however, to be 
exclusively associated with K cells (39). MacFarlan demon­
strated that in SFV infections, the Ab-dependent early 
effector cells were macrophages and an Ab independent 
NK cell appeared later in the infection (41). 
Cytotoxicity also was studied by Rola-Pleszcznski 
who demonstrated that human T lymphocytes, previously 
sensitized to rubella virus, destroyed rubella-infected 
baby hamster kidney (BHK-21) target cells without the 
production of soluble lyrnphokines (57). Inada et al. also 
characterized a T-cell-mediated cytotoxicity system against 
mouse adenovirus-infected targets (29). In this system, 
the cytotoxicity was present only when effector and target 
cells were from animals which shared the same H-2 restiction, 
but inhibition of viral replication was not limited to one 
particular virus nor was interferon involved in the immuno­
logical reaction. T-cell cytotoxicity also was investigated 
by Centifanto et_ al. in which the release of a lymphokine 
was associated with the cytotoxic activity against HSV-
infected monolayers (7). This mediator, isolated after 
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T cell incubation on infected monolayers, was not interferon. 
In resolving the mechanisms of nonspecific immunity 
against viral infections, several parameters must be con­
sidered as potential solutions: these include increased 
phagocytosis of virions by activated macrophages, cytotox­
icity of viral target cells by immunological cells or med­
iators, compartmentalization of infectious virus and the 
production of interferon or other antiviral mediators. 
One particular model to define these mechanisms has been 
developed by Lodmell and Ewalt (39. 4-0). In this system, 
nonviable Mycobacterium tuberculosis, strain Jamaica, 
suspended in an oil-in-saline emulsion, was used to induce 
nonspecific resistance to encephalomyocarditis virus (EMCV) 
infection (39). The mycobacteria emulsion, when injected 
i.p. or i.Vi, induced resistance to E.VIC.V challenge by any 
of four routes; intramuscularly (i.m.), i.p., i.v., or s.c.. 
This viral resistance was maintained from 1-12 weeks post-
sensitization with the mycobacteria, and after EMCV challenge, 
less than 50% of the surviving mice possessed circulating 
anti-E;v'ICV Ab and none had detectable serum interferon. 
Experiments to quantitate EMCV in the spleen, liver and 
sera of normal and mycobacteria-sensitized mice indicated 
that mice were protected by a mechanism which inhibited 
early viral replication and spread of the virus to the CNS. 
T-0 further characterize the mechanisms of protection 
in this model, Lodmell and Ev/alt selectively removed or 
temporarily inactivated various components of the immune 
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system in vivo (40). A rapid elimination of infectious 
virus from the circulation by phagocytic cells did not 
appear to be the mechanism of protection because similiar 
concentrations of virus were found in sera of mycobacteria-
sensitized and normal mice from 1-120 minutes after EMCV 
challenge. Some of the mycobacteria-sensitized mice that 
survived EMCV infection were viremic 72 h post-virus chalr-
lenge which indicated that the virus did replicate in these 
mice. Furthermore, mice splenectomized prior to sensiti­
zation with mycobacteria were resistant to viral challenge, 
whereas, splenectomies performed after mycobacteria admini­
stration resulted in death of mice challenged with EMCV. 
The spleen was postulated to harbor effector cells in mice 
although in its absence, mycobacteria appeared to localize 
in areas that were sufficient to enhance resistance to a 
lethal challenge of EMCV. In addition, neonatally thymec-
tomized mice or athymic nude mice sensitized with the 
mycobacteria emulsion were resistant to EMCV. When myco-
bacteria-sensitized mice were injected i.p. with silica, 
a putative macrophage inactivator, resistance to EMCV was 
abolished. The number of macrophages and lymphocytes in 
the PC population had decreased ninefold after silica treat*-
ment while the number of neutrophils doubled. In addition, 
i.p. administration of cyclophosphamide, an immunosuppressant, 
2 days prior to virus challenge decreased the number of PC 
threefold and abrogated resistance of mycobacteria-sensitized 
mice to EMCV. Thus, the effector cell based on these in 
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vivo studies appeared to be a macrophage acting indepen­
dently of T: cells. The mode of action of these effector 
cells was not clearly evident and in order to further 
define this system of nonspecific resistance, studies were 
continued in an in vitro tissue culture model (Lodmell and 
Ewalt, personal communication). In this tissue culture 
system, EMCV-infected mouse embryo fibroblast (MEF) 
monolayers were overlaid with unseparated peritoneal cells 
(PC) from either mycobacteria-sensitized or normal mice 
at a PC-to-MEF ratio of 20. Cultures incubated with PC 
from mycobacteria-sensitized mice were found to contain 
significantly less virus at 18 h than those with PC from nor­
mal mice (Pusateri, jet a^L. , manuscript accepted for publication). 
The purpose of the research presented in this thesis 
is to define the in vitro mechanisms for inhibition of EMCV 
replication by PC from mice sensitized with nonviable 
M. tuberculosis. With this model, such factors as temper­
ature, pH and replenishment of nutrients during the course 
of infection will be monitored for their effects on viral 
replication. Enhancement of viral inhibition will be 
attempted by varying doses of mycobacteria, collection of 
PC at different intervals after the injection of the myco­
bacteria emulsion, and using different MEF monolayers for 
the assay in order to define the parameters for maximal 
in vitro inhibition. Furthermore, kinetic studies will 
determine the interval necessary for contact between effector 
cells and infected MEF cells to inhibit viral replication. 
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Various multiplicities of EMCV infection and cytotoxicity 
assays will be done to determine the importance of viral 
spreading to uninfected monolayers. Athymic nude mice 
will be administered the mycobacterial emulsion and their 
PC tested in vitro. Furthermore, supernatant fluids from 
PC cultures will be screened for antiviral mediators and if 
found, the active factor(s) will be characterized. 
The present experiments show that PC from mice sensi­
tized 2-10 weeks previously with 50-500 ug of mycobacteria 
inhibit EMCV replication when incubated at a 20:1 effector-
to-target cell ratio on MEF monolayers infected with 5-7 
plaque forming units (PFU) of EMCV. Kinetic studies indicate 
that PC and infected MEF must be in contact for 8-10 h be­
fore detectable (> 1 log^g or > 90%) inhibition is observed. 
Inhibition of EMCV replication is not due to unfavorable 
in vitro environmental conditions nor due to cytotoxicity 
of monolayer cells, yet EMCV is prevented from spreading 
to uninfected MEF cells. PC cultures from mycobacteria-
sensitized mice have been found to produce an immune (type II) 
interferon that is similiar, but not identical to classical 
type II interferon. It appears that the immune interferon 
is responsible for the nonspecific inhibition of EMCV 
replication. 
MATERIALS AND METHODS 
Mice All mice were derived from stocks maintained 
at the Rocky Mountain Laboratories (RML), Hamilton, MT. 
One to three month old C57BL/lOScN mice, unless noted other­
wise were used for mycobacteria sensitization. Mouse 
embryo fibroblasts monolayers (MEF) were prepared from 
Carworth Farms Webster mice (CFW/R) and 19-21 day old 
Swiss Webster mice were used to prepare an encephalomyo-
carditis virus (EMCV) pool. BALB/c (nu/+) and athymic 
(nude) mice (nu/nu, produce by successive cross-intercross­
ing onto a BALB/c backround) were used in some sensitization 
studies. The nude mice were maintained in a special animal 
room in conventional autoclaved cages with filter caps, 
sterilized bedding and water bottles. Sterilized food and 
water were supplied ad libitum. 
Preparation of Mycobacterial Emulsion Acetone dried 
Mycobacterium tuberculosis, strain Jamaica, was provided 
by Dr. Carl Larson, University of Montana, Missoula, MT. 
The culture was isolated from a fatal case of tuberculosis 
in 1933 by Drs. J. Freund and E. Opie (personal communication, 
Dr. George Kubica, Center for Disease Control, Atlanta, GA). 
Twenty-five mg of autoclaved and heat-dried mycobacteria 
was suspended in 8 drops of a sterile light mineral oil 
(Drakeol 6VR, Pennsylvania Refining Co., Butler, PA). This 
suspension was ground to a smooth consistency using a drill 
press rotating at 800 RPM in a sterile tissue grinder 
19 
20 
equipped with a Teflon pestle (Scientific Glass Apparatus 
Co., Inc., Bloomfield, N.J.). After heating the mixture for 
5 min at 75°C, 10 ml of preheated (75°C) 0.15M NaCl with 
0.2% tween 80 was added, and the mixing v/as continued for 
another 5 min. Finally, the uniform emulsion was heated 
to 65°C for 30 min. <i/hen properly prepared, the mycobacteria 
were associated with the oil droplets. Viable mycobacteria 
were not detected after culturing the emulsion on Dubos 
plates. 
Sensitization of Mice with Mycobacteria C57BL/lOScN 
mice were injected i.p. or i.v. with 0.2 ml of the oil 
emulsion which contained 500 ug of mycobacteria, unless 
otherwise noted. Control mice were either untreated or 
injected with the oil emu Is.ion without mycobacteria (TSO). 
Viruses EMCV was obtained from Dr. Michael Ross, NIH,. 
Bethesda, MD. A stock pool was prepared by the intracerebral 
(i.e.) injection of 19-21 day old Swiss Webster mice with 
2 x 10-^ PFU/0.03 ml. Twenty-four hours later, the brains 
were harvested, weighed, homogenized in a blender and frozen 
in one ml quantities at -70°C. The stock EMCV preparation 
contained 9.5 x 10^ PFU/ml. 
Vesicular Stomatitis Virus (VSV), Indiana strain, ob­
tained from the American Type Culture Collection, Rockville, 
MD was grown and assayed in primary rabbit kidney (PRK) and 
mouse L (ML) cells. The stock pool contained 1 x 10^ PFU/ml 
in PRK cells and 1 x 10^ PFU/ml in ML cells. 
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Herpes Simplex Virus, type 2 (HSV-2), strain 196 ob­
tained from Dr. Carl Larson, University of Montana, Missoula, 
MT was prepared and assayed on PRK cells and contained 
2.6 x 10? PFU/ml. 
Vaccinia Virus (VV), strain MR69-2, also obtained from 
Dr. Larson, was grown and assayed on PRK cells, and had a 
titer of 7.2 x 10^ PFU/ml. 
Media Media for growing tissue culture cells consisted 
of Eagle Minimal Essential Media (MEM) (Grand Island Bio­
logical Co., Grand Island, N.Y., catalog #F-15) containing 
10% fetal calf serum (FCS), 200 units/ml of penicillin G 
(Eli Lilly and Co., Indianapolis, IN), and 1 ug/ml of 
amphotericin B (E.R. Squibb and Sons, Inc., Princeton, N.J.) 
(MEM-10). Dilutions of MEM-10 were made in MEM without 
FCS and were used in different assays. Dulbecco's phosphate 
buffered saline (PBS) with Ca and Mg was used to wash 
monolayers and cell suspensions. 
Tissue Culture Cells Primary mouse embryo fibroblasts 
(MEF) were prepared from CFW/R mouse embryos. After re­
moval of heads, arms, legs and tails, the remaining torsos 
were cut into small sections which were suspended in 100 ml 
of 0.25% trypsin (Difco trypsin 1:250, Detroit, MI) in 
Dulbecco's PBS with 2% FCS. The suspension was trypsinized 
at 4°C for 18-24 h in a 200 ml trypsinizing flask and then 
was strained through sterile gauze into 4-50 ml centrifuge 
tubes containing 5 ml of FCS. After centrifugation at 
300 x g for 10 min and two washes with 50 ml of MEM-10, 
22 
10-15 ml of 0.63^ tris NH^Cl was added to the cells to 
lyse erythrocytes. The cells were held at room temperature 
for 5-10 min, diluted with 35-^0 ml of MEM-10 and the cells 
centrifuged again. A stock pool of MEF' cells was prepared 
by planting 1 x 10^ cells/ml in 40 ml of MEM-10 in a 150 cm^ 
tissue culture flask (Corning, Corning, N.Y.). Monolayers 
which were confluent in 7-10 days were harvested from the 
flasks by incubating the cells at 37°C in 5% 00g in air 
for 10 min in 35 ml of a saline A, trypsin, and versine (STV) 
solution consisting of 0.8% NaCl, 0.04% KC1, 0.1% dextrose, 
0.058% NaHCO^, 0.05% trypsin and 0.02% versine. The cell 
suspension was added to a 50 ml centrifuge tube with 5 ml 
of FCS and centrifuged at 300 x g for 10 min. Cells were 
washed twice in MEM-10 and resuspended in MEM supplemented 
with 20% FCS and 10% dimethyl sulfoxide (DMS0) (J.T. Baker 
Chemical Co., Phillipsburg, N.J.) (4 ml/150 cm^ flask). 
One ml of the cell suspension was distributed into ampoules 
(Wheaton Scientific, Milleville, N.J.) and sealed with a 
Hp and Op torch. The ampoules then were precooled in a 
95% alcohol bath at -70°C for 4-24 h and subsequently 
stored in liquid Np. Secondary MEF cells were used for the 
in vitro viral inhibition and interferon assays by adding 
the cells from one ampoule to 25-75 ml of MEM-10 and distri­
buting one ml quantities of this solution into the wells of 
a TC-24 plate (16 mm diameter wells, Linbro, Division of 
Flow Laboratories, Hamden, CT). Monolayers were confluent 
after 2-4 days of incubation at 37°C in 5% OO2 in air. 
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Viral titrations were performed in the following cells* 
Mouse L (ML) cells, provided by Dr. R.K. Gerloff, 
ML, Hamilton, MT, were used for VSV, EMCV, and interferon 
titrations. The cells from one freezing ampoule were diluted 
in 75-300 ml of MEM-10 and planted in TC-24 plates as with 
the MEF; monolayers were confluent in 1-3 days. 
PRK cells, provided by Larry Ewalt, RML, Hamilton, MT, 
were used for HSV and VV titrations. 
The following tissue culture cells also were used 
during the course of the investigation: 
Baby hamster kidney (BHK-21) cells were obtained from 
Grand Island Biological Co., Grand Island, N.Y.. 
Primary chick embryo fibroblasts (CEF) were supplied 
by Mort Peacock, RML, Hamilton, MT. 
CER (chick embryo cells contaminated with hamster 
embryo cells) were provided by Dr. Abigail Smith, Yale 
University,, New Haven, CT. 
Crandell feline kidney (CRFK) cells were provided by 
Dr. David Porter, UCLA School of Medicine, Los Angeles, CA. 
Human embryo kidney (HEK) cells were supplied by Dr. 
Richard Ushijima, Department of Microbiology, University of 
Montana, Missoula, MT. 
VERO (African green monkey kidney cells) were purchased 
from the American Type Culture Collection (#CCL-8l). 
Stock pools of the tissue culture cell lines (ML, BHK-21, 
CER, CRFK, HEK, and VERO) were prepared by diluting the cells 
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from one freezing ampoule into a 150 crrT flask containing 
40 ml of MEM-10 and incubating the flasks at 37°C in 5f° 
COp in air until a confluent monolayer was present. The 
cells were removed with 35 ml °f STV as before, placed in 
a 50 ml centrifuge tube with 5 ml of FCS and centrifuged 
at 300 x g for 10 min. The cell pellet was resuspended 
in 10 ml of MEM-10, distributed in 1 ml quantities to 
150 cm^ flasks containing 40 ml of MEM-10 and the cells 
were incubated until monolayers were confluent. The cells 
then were frozen in ampoules as described previously. 
PC Harvest Mice were killed by spinal dislocation 
and injected i.p. with 4-5 ml of Dulbecco's PBS containing 
5 units of heparin per ml. After massage, the peritoneum 
was pierced over an open centrifuge tube and the cells and 
washings collected. PC from individual mycobacteria-
sensitized, TSO-injected, or normal mice were collected 
in separate pools and Dulbecco's PBS with heparin was added 
to equilibrate the volumes. The PC were centrifuged at 
300 x g for 5 min at 4°C, washed in Dulbecco's PBS, and 
5 ml of prewarmed (37°C) 0.83'% tris AH^CI was added. After 
the cells had been incubated for 5 min at room temperature, 
the tris NH^Cl was diluted in Dulbecco's PBS. The cells 
then were centrifuged as before and resuspended at a con­
centration of 5 x 10^ PC/ml in MEM plus 2% FCS (MEM-2). 
Trypan blue exclusion determinations indicated that the 
PC were consistently > 90% viable. 
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Spleen Cell Harvest Spleens were removed from myco­
bacteria-sensitized or normal mice and held in Dulbecco's 
PBS with heparin before the cells were gently scraped from 
the splenic sac with small sterile curved forceps. The 
entire solution then was placed in a 50 ml centrifuge 
tube and the larger fragments of spleen were allowed to 
settle for 5 min. The remaining cell suspension was poured 
into a fresh centrifuge tube and a series of washes and 
lysis of erythrocytes was performed as with the PC. 
Spleen cells were resuspended in MEM-2 at 5 x 10^ cells/ml. 
Trypan blue staining indicated that the cells were > 90c/o 
viable. 
In Vitro Viral Inhibition Assay MEF monolayers in 
TC-24 plates were infected with 5-7 PFU of EMCV in 0.2 ml 
of MEM. After adsorption for 2 h at 37°C. in 5$ OOp in 
air, the EMCV was aspirated and the monolayers were washed 
with Dulbecco's PBS. Unless otherwise noted, PC from mice 
injected 2-6 weeks previously with mycobacteria or PC from 
normal mice, suspended in 1 ml of MEM-2 were added to in­
fected monolayers at a PC-to-MEF ratio of 20 (5 x lO^PC). 
After incubation for 18 h at 37°C in 5% C02 in air, entire 
cultures were harvested by scraping the cells from the 
plastic wells with the plunger of a sterile plastic dis­
posable 1 cc tuberculin syringe. Samples were frozen at 
-70°C before titration. Duplicate samples were included in 
all assays and each experiment was conducted a minimum of 
three times. 
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Virus Titrations EMCV, VSV, and VV were titrated in 
plaque assays utilizing a 0.75$ methocellulose (Fisher 
Scientific Co., Fair Lawn, N,J.) in MEM-10 as an overlay 
media to prevent secondary plaquing. The overlay media 
was prepared by separately sterilizing 3 g of methocellulose 
and 200 ml of distilled water and combining the two immed­
iately after autoclaving. After 2 h of mixing at 60°C, 
the media was cooled to 40°C and 200 ml of prewarmed 2X 
MEM-10 was added. The entire solution then was spun for 
another 2 h at room temperature and cooled at 4°C overnight. 
To titrate virus, a series of 10 fold dilutions were made 
for each sample in MEM and 0.2 ml of each dilution was used 
to infect duplicate ML (for EMCV or VSV) or PRK (for VV) 
monolayers in TC-24 plates. After a 2 h adsorption period 
the virus was aspirated and monolayers were washed with 
Dulbecco's PBS and overlaid with the methocellulose media. 
Twenty-four hours post-infection (for EMCV) or 48 h post­
infection (for VSV or VV), the overlay media was aspirated 
and monolayers were washed with Dulbecco's PBS, fixed with 
95fa alcohol, and stained with a 0.8$ giemsa solution pre­
pared in 50$ methanol and 50$ glycerol. Plaques were 
counted and titers expressed as PFU/0.2 ml, log10. 
HSV-2 titrations were similiarly done in FRK cells but 
MEM-10 supplemented with 2% human sera containing HSV anti­
bodies was used as the overlay media. Monolayers were 
fixed and stained at 48 h. 
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Killing of PC PC were killed either by heating at 
56°C for 30 min or sonication with a Bronwill Biosonik III 
for 45 seconds at maximum intensity. The cells were 10$ 
viable after either treatment. Media in which the cells 
were lysed also was tested for antiviral activity. 
pH Determinations The pH of various MEF cultures was 
recorded with a standard pH meter (Beckman-Expandomatic IV) 
18 h post-infection and just prior to harvest of cultures. 
Measurements were done quickly to avoid pH changes that 
result when cultures are brought from an enriched COp 
environment into the atmosphere. To avoid cross contam­
ination, the electrode was cleaned with 70$ alcohol between 
measurements. 
Supernatant Fluid Preparation PC from mycobacteria-
sensitized or normal mice suspended in MEM-2 at a concen-
tration of 5 x 10 cells/ml were incubated at 37°C in 
5$ COp in air in 35 mm plastic tissue culture dishes 
o 
(Corning, Corning, N.Y.) or 25 cm tissue culture flasks 
(Co-Star, catalog #220-46, Cooke Laboratory Products, 
Alexandria, VA). At 18 h, unless stated otherwise, the 
supernatant fluids were removed, centrifuged at 300 x g for 
5 min at 4°C and stored at -30°C. Supernatant fluids were 
diluted ls2 (unless stated otherwise) in MEM-2 and tested 
in interferon assays or for antiviral activity on EMCV-
infected MEF monolayers. 
Peritoneal Wash Preparation The Dulbecco's PBS plus 
heparin washings used to harvest PC from mycobacteria-sensi-
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tized or normal mice were concentrated 10-20 fold by vacuum 
pressure at 4°C after removal of the FC. Concentrated 
fluids subsequently were diluted 1:2 in MEM plus 4$ FCS 
(MEM-4) and tested for antiviral activity on EMCV-infected 
MEF monolayers. 
Mouse Serum Collection Mice anesthetized with ether 
were bled from the brachial artery. Blood from mycobacteria-
sensitized or normal mice was pooled, held at room temper­
ature for 30-60 min and then centrifuged at 1550 x g for 
15-30 min. Serum was removed and heat inactivated for 
30 min at 56°C before storing at -5°C. Dilutions of serum 
in MEM were tested for interferon and antiviral activity on 
EMCV-infected MEF monolayers. 
Replenishment of Culture Nutrients During EMCV Infection 
EMCV-infected MEF monolayers, incubated with 1 ml of PC 
(5 x 10^ PC) from mycobacteria-sensitized or normal mice 
or 1 ml of MEM-2 alone, were refed with 1 ml of fresh MEM-2 
at 5 or 10 h post-infection or with 0.5 ml of fresh MEM-2 
at both 5 and 10 h post-infection. Entire cultures were 
harvested and titrated as usual. 
Refeeding PC Cultures from Mycobacteria-Sensitized Mice 
for Supernatant Fluid Harvest Supernatant fluids harvested 
from 18-24 h PC cultures were prepared as previously des­
cribed with the exception that after the fluids were 
removed and centrifuged, nonadherent cells remaining in the 
pellet and adherent cells on the flask were washed with 
Dulbecco's PBS. All the cells were subsequently resuspended 
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in a similiar amount of fresh MEM-2 as was removed and 
reincubated. This procedure was repeated every 18-24 h 
for a week. 
Interferon Assay Supernatant fluids from PC cultures 
of mycobacteria-sensitized or normal mice and serum from 
similiar mice were assayed for interferon on ML and MEF 
cells. In all assays, two standard type I interferons 
were used; the first was a reference sample prepared in 
murine L929 cells by inoculation with Newcastle Disease 
Virus (NDV) and contained 1600 units/ml (Lot #G002-904-511. 
supplied by the Research Resources Branch, NIAID, NIH, 
Bethsada, MD). The second standard type I interferon, 
prepared at RML, was sera harvested from mice 2 h following 
i.v. inoculation with 50 ug of poly (I)-poly (C) (from the 
Research Resources Branch); this type I interferon contained 
4000 units/ml. Two standard type II immune interferons 
also were included in these assays. One was obtained from 
Dr. Ruth Neta (University of Notre Dame, Notre Dame, IN) 
and v/as prepared in mycobacteria-sensitized mice that were 
challenged i.v. with old-tuberculin (OT); it contained 
800 units/ml. A second standard type II interferon was 
provided by Dr. Jerzy A. Georgiades, (University of Texas 
Medical Branch, Galvaston, TX) and contained 10 units/ml. 
To perform the assay, 0.5 ml of the various fluids at 
similiar concentrations of activity were overlaid on unin­
fected MEF or ML monolayers in TC-24 plates and incubated 
for 24 h (unless otherwise noted) at 37°C in 5$ COp in air. 
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The fluids then were removed and the monolayers were washed 
with Dulbecco's PBS and challenged with 10-15 PFU of either 
EMCV or VSV. After a 2 h viral adsorption, the monolayers 
were washed and overlaid with methocellulose and the plates 
were incubated at 37°C in 5$ 00 2 in air for 20-24 h (for 
EMCV) or 48 h (for VSV). The plates were fixed and stained 
as before for plaque enumeration. A fluid was considered 
positive for interferon activity if it inhibited plaque 
formation by > 50$ as compared to viral control wells 
incubated without an interferon sample. Interferon titers 
were expressed as the reciprocal of the highest dilution 
of the supernatant fluid that inhibited plaque formation 
by 50$. 
Characterization of the Mediator in Supernatant Fluids 
Antiviral activity in supernatant fluids containing similiar 
units of activity was characterized as follows: 1) Acid 
stability was measured by dialyzing samples for 24 h at 
4°C against 1 liter of 0.1M pH 2 glycine HC1 buffer. After 
24 h the acid buffer was removed and 1 liter of Dulbecco's 
PBS (pH 7.2-7.4) v/as added. The fluids were dialyzed for 
another 24 h at 4°C before they were removed from the dialysis 
tubing. 2) Heat stability consisted of heating fluids at 
56°C for 0.5. 1 and 2 h. 3) Trypsin sensitivity was deter­
mined by incubating the fluids v/ith 1.25 mg/ml of trypsin 
for 5 h at 37°C. The trypsin v/as inactivated by adding 
0.5 ml of FCS. 4) Size estimations of the active molecule 
were done by filtering the fluid through a 0.22 u filter 
31 
(Swinnex catalog #SXGS 025 LS, Bedford, MA) and by ultra-
centrifugation at 100,000 x g for 1 h. 5) Ten to 20 fold 
concentrations were done in dialysis tubing under vacuum 
pressure at 4°C. 
After each treatment, the samples were diluted 1:2 
in MEM-4 (for #1), or in MSM-2 (for #2, 3 and 4) or MEM 
(for #5) and assayed for interferon activity on MEF or ML 
cells as described previously. 
Preparation of Supernatant Fluids in PC Cultures In­
cubated with old-tuberculin (0T) or Purified Protein Deriva­
tive (PPD) Supernatant fluids were prepared with PC from 
mycobacteria-sensitized mice or normal mice as previously 
described with the exception that cultures were incubated 
with either 50 ug of OT (Jensen-Salsbery Laboratories, 
Kansas City, MO) or 50, 100 or 500 ug of PPD (Parke, Davis 
and Co., Detroit, MI). Controls consisted of PC incubated 
without the mycobacterial antigens or MEM-2 incubated with 
various amounts of OT or PPD. 
Cytotoxicity Assay Uninfected MEF monolayers were 
labeled with ?. uCi of Nap^CrO^ (New England Nuclear, Boston, 
MA) in 0.2 ml of MEM for 2 h at 37°C in 5$ C02 in air. After 
incorporation of the radiolabel, the monolayers were washed 
three times with Dulbecco's PBS and either infected with 
5-7 PFU of EMCV in 0.2 ml of MEM or overlaid with 0.2 ml of 
MEM alone. Two hours later, monolayers were washed and over­
laid with PC from mycobacteria-sensitized and normal mice 
or supernatant fluids harvested from K! cultures from sim-
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iliar mice. Eighteen hours later, the culture fluids from 
all samples were harvested, centrifuged at 300 x g for 
10 min and 0.5 ml of fluid was assayed in a gamma counter 
(Nuclear Chicago) to determine the amount of ^lgr present. 
The maximum amount of ^Cr that could be released from the 
monolayers was determined by incubating monolayers with 
MEM-2 and harvesting the cultures in their entirity. These 
samples were frozen and thawed three times, spun at 300 x g 
for 10 min and 0.5 ml of fluid was assayed in the gamma 
counter. To calculate the percent of 5^-Cr released, the 
amount of ->*Cr measured in the samples overlaid with PC or 
supernatant fluids was divided by the maximum amount of 
^Cr that was released by freezing and thawing of the cells. 
EMCV Neutralization Assay Thirty PFU of EMCV in 0.3 ml 
MEM was incubated at 37°C with an equal amount of an un­
diluted or a 1:2 dilution of an active supernatant fluid 
for 1, 2, 4, 8, 12, 18 and 24 hours. After incubation the 
samples were titrated for EMCV in ML cells. Controls con­
sisted of EMCV incubated with supernatant fluids from PC of 
normal mice or media alone. 
Anti-Interferon Assay Rabbit anti-type I and anti­
type II mouse interferon antibodies were tested in a 
neutralization assay with supernatant fluids from PC cultures 
of mycobacteria-sensitized mice. Rabbit anti-L cell inter­
feron globulin (anti-type I interferon) was supplied by 
Dr.June Dunnick, Development and Application Branch, Micro­
biology Infectious Disease Program, NIAID, NIH, Bethesda, MD, 
and rabbit anti-mouse type II interferon was supplied by 
Dr. Jerzy A. Georgiades, University of Texas Medical branch, 
Galvaston, TX. Anti-interferon antibodies were diluted in 
MEM-2 to concentrations that neutralized 10 units of homo­
logous interferon; normal rabbit globulin (NRG) was used 
as a control at similiar concentrations. Supernatant 
fluids and known type I and type II interferons were diluted 
to 1-4 units/0.11 ml and incubated at 37°0 for 30 min with 
0.11 ml of the antisera or NRG. One-tenth ml of these 
mixtures then were incubated on duplicate uninfected MEF 
monolayers in TC-96 plates (6 mm diameter, Linbro Scientific, 
Inc., Flow Laboratories, Hamden, CT) for 24 h at 37°C in 
5$ COp in air before they were challenged with 10-15 PFU of 
VSV/0.025 ml. Because of the small size of the monolayer 
wells, plates were fixed and stained for plaque enumeration 
at 24 h rather than the usual 48 h. Interferon activity 
was expressed as > 50$ reduction in the number of plaques 
present in virus-infected control wells. 
RESULTS 
Inhibition of E:.;iCV replication by PC from mice sensi­
tized with nonviable M. tuberculosis. The data in Table 1 
indicate that PC from mice sensitized with 500 ug of 
M. tuberculosis, as compared to PC from normal mice, inhibit 
EMCV replication when incubated with infected MEF monolayers 
at a PC-to-MEF cell ratio of 20; viral replication was 
inhibited by> 2 log^Q or > 99% with PC from mice sensitized 
either i.p. or i.v. with mycobacteria. At lower PC-to-MEF 
cell ratios, PC from i.p. sensitized mice were more effect­
ive. PC from mice injected with the oil emulsion without 
mycobacteria were not inhibitory (data not shown). In view 
of these results, all subsequent experiments, unless noted 
otherwise, were done with PC from i.p. sensitized and un­
treated mice at PC-to-MEF cell ratios of 20. 
Inhibition of EMCV replication by PC from mice sensi­
tized with various concentrations of nonviable M. tuberculo­
sis. In an attempt to enhance the inhibition of viral 
replication, various concentrations of mycobacteria were 
administered i.p. and PC were tested three weeks later in 
the inhibition assay. The data in Table 2 demonstrate that 
inhibition was not dose dependent; that is, doses of 50-500 
ug of mycobacteria were equally effective. Because previous 
in vivo studies utilized $00 ug of mycobacteria in the 
emulsion for sensitization (39), for consistency the same 
concentration was used for the remainder of these studies. 
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TABLE 1 Inhibition of EMCV Replication by PC from Mice 
• (a) 
Sensitized with Nonviable M. tuberculosis^ ' 
Route of M. 
tuberculosis 
Effector to Target Cell Ratio 
20 10 5 
injection (PFU/0.2 ml, log10) 
i.p. 4.1 4.3 5. 1 
i. v. 4.0 5.2 6. 2 
none, Normal PC 6.4 6.3 6. 4 
(a) MEF monolayers that had been infected for 2 h with 5-7 
PFU of EMCV were incubated with different concentrations 
of PC from normal mice or mice that had been injected with 
500 ug of mycobacteria 3 weeks previously. After 18 h 
incubation, entire cultures were harvested and titrated 
for virus. In the absence of PC, the virus titer was 
106,4 PFU/0.2 ml, log10. 
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TABLE 2 Inhibition of EMCV Replication by PC from Mice 
Sensitized with Different Concentrations of Nonviable 
(a) 
M. tuberculosis 
ug of M. tuberculosis Inhibition of EMCV 
per mouse Replication, log10^b^ 
50 
100 
250 
500 
1000 
none, Normal PC 
2 .0  
2.9 
2.3 
2.5 
1.7 
none 
(a) MEF monolayers that had been infected for 2 h with 
5-7 PFU of EMCV were incubated at a PC-to-MEF ratio of 20 
with PC from normal mice or mice that had been sensitized 
i.p. 3 weeks previously with various concentrations of non­
viable mycobacteria,, Cultures were harvested 18 h after 
infection and virus titers determined. 
(b) Inhibition of EMCV replication was determined by com­
paring viral titers of cultures incubated with PC from 
normal and mycobacteria-sensitized mice. Cultures incubated 
without PC had viral titers comparable to cultures incubated 
with normal PC. 
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Inhibition of viral replication with PC harvested at 
different intervals post-mycobacteria sensitization. Prior 
in vivo experiments have shown that mice were protected 
against a lethal challenge of EMCV from 1-12 weeks after 
administration of the mycobacterial emulsion (39). To 
determine the intervals that PC from mycobacteria-sensitized 
mice were effective in vitro. PC were removed from mice at 
various times post-mycobacteria sensitization. The data in 
Table 3 indicate that PC from mice sensitized i.p. 2-10 
weeks previously with 500 ug of mycobacteria markedly 
inhibit viral replication (_> 1 log1Q or > 90%); maximal 
inhibition occurs with PC. harvested 2-6 weeks post-sensi-
tization. It has been possible, however, to demonstrate 
inhibition of viral replication with PC from some mice 
that were sensitized 15 weeks previously with mycobacteria. 
Hereafter FC were harvested for experiments 2-6 weeks 
post-mycobacteria sensitization. 
Effects of various temperatures on in vitro inhibition 
of EMCV replication. To determine whether PC from myco­
bacteria-sensitized mice would be more effective if the 
rate of EMCV replication was reduced, an attempt to slow 
viral growth was made by incubating infected monolayers 
with PC from mycobacteria-sensitized mice at lower temper­
atures. The data in Table 4 indicate that at the lower 
temperatures of 30.5°C or 33°C. 1.2 and 1.0 l.og10 of inhibi­
tion was observed. In contrast, at 37°C, inhibition of 
TABLE 3 Inhibition of EMCV Replication by PC Harvested at 
Various Intervals After Sensitization with Nonviable 14^ 
. (a ) 
tuberculosis^ ' 
Weeks post-injection 
of mycobacteria 
Inhibition of EMCV 
Replication, log-j^13^ 
1 
2 
3 
4 
5 
6 
7 
8 
10 
15 
20 
0.4 
2.4 
2.2 
2.1 
1.5 
2 .0  
1.4 
1.3 
1 . 0  
0.4 
0.1 
(a) MEF monolayers that had been infected 2 h previously 
with 5-7 PFU of EMCV were incubated at PC-to-MEF ratios of 
20 with PC from normal mice or mice that had been injected 
i.p. with 500 ug of nonviable mycobacteria. 
(b) Inhibit ion of EMCV replication was determined by com­
paring viral titers of cultures incubated with PC from 
mycobacteria-sensitized and age-matched normal mice. Cul­
tures incubated without PC had viral titers comparable to 
monolayers incubated with normal PC. 
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TABLE 4 Effect of Temperature on Inhibition of EMCV Repli-
(a ) 
cation by PC from Mycobacteria-Sensitized Micev ' 
Temperature PC Source Inhibition 
(°C) Mycobacteria- Normal None of EMCV 
sensitized Replication 
(PFU/0.2 ml, log1&) (log10)(b) 
30.5 3.7 4.9 5-0 1.2 
33 4.4 5.4 5.3 1.0 
37 3-5 5-7 6.0 2.2 
(a) MEF monolayers that had been infected 2 h previously 
with 5-7 PFU of EMCV were incubated at different tempera­
tures with media or PC at PC-to-MEF ratios of 20. Cultures 
were harvested 18 h after infection and virus titers deter­
mined . 
(b) Inhibition of EMCV replication v/as determined by com­
paring virus titers of cultures incubated at similiar 
temperatures with PC from normal and mycobacteria-sensitized 
mice. 
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viral replication was 2.2 log^Q. Furthermore, it is shown 
that EMCV replication in cultures without PC also was max­
imal at 37°C. Thus, it appears that the optimal conditions 
for both viral growth and the inhibitory functions of PC 
is 37°C. Hereafter all experiments were done at this 
temperature. 
Effect of PC from mycobacteria-sensitized C57BL/lOScN 
mice on EMCV replication in MEF monolayers prepared from 
different strains of mice. MEF monolayers were prepared 
from three strains of mice to determine if there was a 
variation in the inhibition of EMCV replication in the 
different cells. Outbred Swiss Webster, inbred C57BL/lOScN 
and outbred CFW/R mouse embryo fibroblasts were infected 
with 5-7 PFU of EMCV and incubated with PC from mycobacteria-
sensitized and normal C57BL/lOScN mice. The data in Table 5 
show that maximum inhibition was observed in CFW/R mono­
layers (> 99cf° inhibition) and that monolayers prepared from 
the syngenic C57BL/lOScN were less effective, although the 
inhibition was > 90%. CFW/R monolayers were used in all 
subsequent assays. 
Effect of pH on inhibition of EMCV replication. EMCV is 
classified as a cardiovirus in the family Picornaviridae 
based on a number of characteristics, among which is 
stability at pH 3 or 8, but lability at pH 6 (17). Because 
PC may have been affecting the pH of the tissue culture 
TABLE 5 Effect of PC from Mycobacteria-Sensitized C57BL/lOScN 
Mice on EMCV Replication in MEF Monolayers Prepared from DifiV 
erent Strains of Mice^a^ 
Strain of Mouse Source of PC 
MEF Monolayer Mycobacteria- Normal 
Sensitized C57BL/lOScN 
C57BL/lOScN 
(PFU/0.2 ml, log10) 
Inhibition 
of EMCV 
Replication 
(lc.g10)(b) 
CFW/R 
RML 
C57BL/lOScN 
3.5 
4.3 
5.1 
6.3 
6.5 
6 . 8  
2.8 
2.2 
1.7 
(a) MEF monolayers prepared from different strains of mice 
were infected with 5-7 PFU of EMCV for 2 h and then incu­
bated at a PC-to-MEF ratio of 20 with PC from C57BL/lOScN 
normal or similiar mice which had been sensitized 3 weeks 
previously with 500 ug of mycobacteria. eighteen hours later, 
cultures were harvested and the virus titers determined. 
(b) Inhibition of EMCV replication was determined by com­
paring viral titers of cultures incubated with PC from myco-
bacteria-sensitized mice and normal mice. Monolayers without 
PC had viral titers comparable to cultures with normal PC. 
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assay through their metabolic processes which ultimately 
would result in an acid media, the pH of the media on 
infected monolayers overlaid with media only or PC from 
mycobacteria-sensitized or normal mice was recorded after 
18 h of incubation at 37°C in 5% COg in air. As observed 
in Table 6, the pH of cultures incubated with PC or with 
media alone were either 7.2 or 7.4 which are optimal for 
EMCV replication. The virus concentration in these cultures 
differed, however, in that there was 2.0 log^Q less virus 
in monolayers incubated with PC from mycobacteria-sensitized 
mice as compared to PC from normal mice. 
Effect of nutrient replenishment on inhibition of 
EMCV replication by PC from mycobacteria-sensitized mice. 
To further substantiate that PC do not inhibit viral repli­
cation by causing an unfavorable environment for virus 
growth, cultures were refed with fresh MEM-2 at various 
times post-infection (Table 7). The data demonstrate 
that PC from mycobacteria-sensitized mice inhibited EMCV 
replication whether or not the cultures were refed with 
fresh media. In fact, a slight enhancement of viral in­
hibition was observed in the refed cultures. 
Effect of nonviable PC from mycobacteria-sensitized 
mice on EMCV replication. To determine if nonviable PC. 
from mycobacteria-sensitized mice inhibited EMCV replication, 
PC were rendered nonviable by heating for 30 min at 56°C 
TABLE 6 Effect of pH on Inhibition of EMCV Replication by 
(a) 
PC from Mycobacteria-3ensitized Mice 
Source of PC pH of Culture PFU/0.2 ml 
- Media ioglO 
Mycobacteria-
sensitized V.2 4.0 
Normal 7.2 6.0 
None 7.4 6.7 
(a) MEF monolayers that had been infected for 2 h with 5-7 
PFU of EMCV were washed and then incubated with media or PC 
at a PC-to-MEF ratio of 20. Eighteen hours post-infection, 
the pH of the cultures was determined, the cultures har­
vested and virus titers determined. 
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TABLE 7 Effect of Nutrient Replenishment on Inhibition of 
EMCV Replication by PC from Mycobacteria-Sensitized Mice^a^ 
Time Post-In­ Source of PC Inhibition 
fection Media Myco- Normal None of EMCV 
Added to bacteria- Replication 
Cultures S ensitized iog10(b) 
(PFU/0.2 ml, log10) 
5 h 4.0 6.3 6.3 2.3 
10 h 4.1 6.1 6.2 2.0 
5 & 10 h 4.2 6.2 6.3 2.0 
none 3-9 5.7 5.5 1.8 
(a) MEF monolayers that had been infected for 2 h with 5-7 
PFU of EMCV were incubated with media or PC at a PC-to-MEF 
ratio of 20. At the intervals noted 1 ml of fresh media 
was added to the cultures, or 0.5 ml of fresh media was 
added to cultures at 2 different times. Eighteen hours post­
infection, cultures were harvested and virus titers determined. 
(b) Inhibition of EMCV replication was determined by com­
paring virus titers between cultures incubated with PC 
from normal and mycobacteria-sensitized mice in the different 
test groups. 
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or rupturing the cells by sonication for 45 seconds with 
Bronwill Biosonik III at maximum intensity. The data in 
Table 8 indicate that nonviable PC at a PC-to-MEF ratio 
of 20 did not inhibit Ei'vlCV replication. Furthermore, media 
in which the PC were rendered nonviable also were ineffec­
tive (data not shown). 
Kinetics of viral inhibition by PC from mycobacteria-
sensitized mice. To determine how rapidly PC from myco­
bacteria-sensitized mice exert their inhibitory effects, 
infected MEF monolayers were incubated with PC, and at 
different intervals thereafter, entire cultures were har­
vested and virus titers determined. The data in Figure 1 
indicate that significant viral inhibition (1 log10 or 90%) 
was not observed until 12 h post-EMCV infection, or 10 h 
after addition of PC to the monolayers. Maximal viral 
inhibition (2 log^Q or 99%) was seen at 18 h post-infection. 
Monolayers incubated with PC from normal mice, or with media 
alone, followed similiar patterns of viral growth through­
out the 18 h incubation period. 
To determine the minimal time PC had to be incubated 
with infected monolayers to inhibit EMCV replication, PC 
were added to monolayers at different intervals after in­
fection, and all cultures were harvested 18 h post-infection. 
MEM-2 incubated with the infected monolayers in which addi­
tion of the PC was delayed, was not removed prior to 
addition of PC. The data in Figure 2 show that PC from 
TABLE 8 Effect of Nonviable PC from Mycobacteria-Sensitized 
Mice on Inhibition of EMCV Replication^^ 
Treatment 
none 
56°C, 30 min 
sonication 
none 
PC Source 
mycobacteria 
mycobacteria 
mycobacteria 
normal 
Viability PFU/0.2 ml,log10 
0% 
10% 
100% 
4.7 
6 . 2  
6 . 1  
5.8 
(a) MEF monolayers that had been infected for 2 h with 5-7 
PFU of EMCV were incubated at an PC-to-MEF ratio of 20 with 
viable PC from normal mice or viable or nonviable PC from 
mice sensitized with 500 ug of mycobacteria. The PC were 
rendered nonviable by heating for 30 min at 56°C or sonica­
tion for 45 seconds with a Biosonik III at maximum intensity. 
Eighteen hours later the cultures were harvested and virus 
titers determined. In the absence of PC, the virus titer 
3 was 10PFU/0.2 ml, 1°S10. 
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Fig 1 Kinetics of Viral Inhibition by PC from ivlycobacteria-
Sensitized Mice 
Monolayers that had been infected with 5-7 PFU of EMCV v/ere 
incubated with PC at a PC-to-MEF ratio of 20. At different 
times after infection, entire cultures were harvested and 
virus titers determined 
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Fig 2 EMCV Replication in Monolayers Incubated with PC from 
Mycobacteria-Sensitized or Normal Mice at Different Times 
After Infection 
MEF monolayers were infected with 5-7 PFU of EMCV for 2 h and 
then overlaid with 1 ml of MEM-2. At the times noted, 1 ml 
of MEM-2 or 1 ml of MEM-2 containing PC at a PC-to-MEF ratio 
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of 20 was added to the existing media on the monolayers. 
All cultures were harvested at 18 h and titrated for virus. 
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mycobacteria-sensitized mice significantly inhibited EMCV 
replication by 2 log^Q (99% inhibition) if they were added 
at 2 or 4 h post-infection. If the addition of PC was 
delayed to 6 or 8 h post-infection, inhibition of replica­
tion was still detected, but its magnitude had decreased to 
1 log^Q (90% inhibition). When PC were added as late as 
12 h post-EMCV infection, no inhibition of viral replication 
was apparent. This data concurs with the results presented 
in Figure 1 in that viral inhibition by PC from mycobacteria-
sensitized mice was not detected unless PC were in contact 
with infected monolayers for a minimum of 10 h (addition of 
PC at 8 h; harvest at 18 h). 
Effect of PC from mycobacteria-sensitized mice on EMCV 
replication in monolayers infected with high multiplicities 
of virus. To further study the inhibitory effect of PC 
from mycobacteria-sensitized mice, 100% of the cells in the 
monolayer were infected. If viral replication was not in­
hibited, this would indicate that reduction of viral titers 
in monolayers infected with a low multiplicity of infection 
(MOI) may in part be due to the inhibition of viral spread 
to uninfected cells. As observed in Table 9. PC from 
mycobacteria-sensitized mice did not inhibit viral replica­
tion when concentrations of virus sufficient to infect 
every cell in the monolayer were used (MOI of 10 and 1). 
In contrast, minimal inhibition occurred with a MOI of 0.5, 
TABLE 9 Effect of PC from Mycobacteria-Sensitized Mice on 
EMCV Replication in Monolayers Infected with High Multipli-
( 3. ) 
cities of Virus 
Multiplicity 
of 
Infection 
PC Source 
Mycobacteria- Normal 
Sensitized 
wone 
(PFU/0.2 ml, log^Q) 
Inhibition 
of EMCV 
Replication 
(b) log 10 
10 
1 
0.5 
0.00004 
(5-7 PFU) 
6.4 
6.5 
6.2 
4.3 
6.5 6.7 
6.5 6.5 
6.7 6.7 
6.3 6.7 
none 
none 
0.5 
2.0 
(a) MEF monolayers that had been infected for 2 h with 
different multiplicities of EMCV were washed and then incu­
bated with media of PC from normal or mycobacteria-sensitized 
mice at a PC-to-MEF r-::tio of 20. Cultures v/ere harvested 
18 h after infection and virus titers determined. 
(b) Inhibition of EMCV replication was determined by com­
paring virus titers of cultures that had been infected with 
similiar concentrations of EMCV and subsequently incubated 
with PC from normal or mycobacteria-sensitized mice. 
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and maximal inhibition (2 log^Q or 99%) was detected when 
5-7 PFU (MOI of 0.00004) were used. 
Inhibition of EMCV replication by PC from mycobacteria-
sensitized mice in the absence of cytotoxicity to monolayers* 
To study in more detail the mechanism of viral inhibition 
by PC, EMCV-infected and uninfected monolayers that had 
been labeled with Na£^1CrO^ were incubated at a PC-to-MEF 
ratio of 20, and the amount of ^Cr released into the super­
natant fluids was determined. The data in Table 10 indicate 
that uninfected monolayers overlaid with PC from mycobacteria-
sensitized or normal mice or monolayers with media alone 
released similiar amounts of -^Cr into the culture media 
after 18 h of incubation. Furthermore, when EMCV-infected 
monolayers were incubated with PC from mycobacteria-sensi-
51 
tized mice, the amount of J Cr released was similiar to 
that detected in uninfected monolayers. In contrast, 17% 
and 21% more *^Cr was released from infected monolayers 
incubated with PC from normal mice or media alone. The 
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increase m ̂  Cr release from these cultures correlated 
with cytopathy consequent to viral replication; viral titers 
were more than 2 log^Q greater than in cultures incubated 
with PC from mycobacteria-sensitized mice. 
In vitro inhibition of EMCV replication by PC from myco­
bacteria-sensitized athymic nude mice. Previous in vivo 
work by Lodmell and Swalt (40) had shown that administration 
TABLE 10 Inhibition of EMCV Replication by PC from Myco­
bacteria-Sensitized Mice in the Absence of Cytotoxicity to 
Monolayers 
Treatment of Monolayers % 51Cr Re­ Virus 
PC Source Virus leased from I'iter̂ K )  
Infection i (a) monolayers FFU/0.2 ml. 
Mycobacteria-
log10 
Sensitized - 44 none 
Normal - 41 none 
None - 44 none 
Mycobacteria-
Sensitized + 40 3.8 
Normal + 57 6.0 
None + 61 6.2 
(a) Na2~^CrO^ labeled uninfected and EMCV-infected (5-7 PFU) 
MEF monolayers were incubated with media alone or PC from 
normal or mycobacteria-sensitized mice at a PC-to-MEF ratio 
of 20. Eighteen hours later the percentage of -^Cr released 
from the cells was determined. 
(b) EMCV replication was determined in separate unlabeled 
MEF monolayers incubated for 18 h with PC from the same mice 
that v/ere used for the ^Cr cytotoxicity assay. 
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of the nonviable mycobacterial emulsion to neonatally 
thymectomized C57BL/lOScN mice or athymic (nude) mice 
protected these animals against a lethal challenge of EMCV. 
Based on this data, it was suggested that the T lymphocyte 
was unimportant in the in vivo mechanism of protection. 
To study this observation .in vitro, PC from mycobacteria-
sensitized nude and euthymic mice were incubated on EMCV-
inf ected MEF monolayers. The data in Table 11 show that 
viral replication was inhibited 2 log^g (99% inhibition) 
with PC from mycobacteria-sensitized nude mice as compared 
to 1.4 log^Q and 1.2 log^0, respectively, with PC from 
mycobacteria-sensitized C57BL/lOScN mice and the BALB/c 
haired littermates. 
Inhibition of Ei-iCV replication with supernatant fluids 
from PC cultures of mycobacteria-sensitized mice. At this 
point the data indicated that an antiviral mediator 
might be responsible for inhibition of viral replication 
because a) marked inhibition (>90%) was not detected unless 
PC were in contact with infected monolayers for 8-10 h 
(Figures 1 & 2), b) cytotoxicity was not detected in 
monolayers incubated with PC (Table 10), and c) PC did not 
inhibit viral replication if every cell in the monolayer 
was infected before addition of the PC (Table 9). To test 
for an antiviral mediator, supernatant fluids were produced 
by incubating PC from mycobacteria-sensitized and normal mice 
for various intervals. The data in Table 12 show that no 
TABLE 11 Effect of PC from Mycobacteria-Sensitized Athymia; 
(a) 
Nude Mice on Inhibition of EMCV Replication 
Source of PC Inhibition of 
Mycobacteria- Normal EMCV 
Sensitized Replication 
(PFU/0.2 ml, log1Q) lo§l0 
C573L/lOScN 4.0 5.4 1.4 
BALB/c haired 
(nu/+) 4.5 5.7 1.2 
Athymic Nude 
(nu/nu) 3«0 5*0 2.0 
(a) MEF monolayers that had been infected with 5-7 PFU of 
EMCV for 2 h were incubated at a PC-to-MEF ratio of 20 with 
PC from normal or mycobacteria-sensitized C57BL/lOScN, and 
BALB/c haired (nu/+) and athymic nude (nu/nu) mice. Eighteen 
hours later cultures were harvested and titrated for virus. 
(b) EMCV inhibition was determined by comparing virus titers 
of cultures incubated with PC from mycobacteria-sensitized 
and normal mice of the same strain. Monolayers without PC 
had a virus titer of 10^*^ PFU/0.2 ml, log^Q. 
Strain of 
Mouse Used 
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activity was detected in 2 h fluids, whereas media harvested 
at 4 h post-incubation had slight activity and media har­
vested thereafter significantly inhibited EMCV replication 
(>90% to >99%). These results agree with the previous 
kinetics data which indicated that an 8-10 h incubation 
period of PC with infected monolayers was necessary before 
significant viral inhibition was detected (Figures 1 & 2). 
After u.v.-inactivation of infectious EMCV, antiviral activ­
ity also was detected in supernatant fluids of cultures in 
which EMCV-infected MEF monolayers were incubated with PC 
from mycobacteria-sensitized mice (data not shown). 
The antiviral supernatant fluids subsequently were 
diluted and tested in an antiviral assay to determine 
their concentrations. The 24 h preparation from this ex­
periment could be diluted 1:32 (data not shown); most active 
supernatant fluids, however, could only be diluted ls8. 
Supernatant fluids from PC of mycobacteria-sensitized athymic 
(nude) mice also contained antiviral activity; in contrast, 
PC from mice injected with TSO or normal mice did not 
release a mediator. Interestingly, active supernatant fluids 
were never detected from PC of mycobacteria-sensitized mice 
that failed to inhibit replication (data not shown). 
Effect of serum and peritoneal washes from mycobacteria-
sensitized mice on EMCV replication. Because a factor in 
supernatant fluids appeared to be involved in the inhibition 
of viral replication, attempts were made to detect antiviral 
TABLE 12 Inhibition of EMCV Replication with Supernatant 
(a) 
Fluids from PC Cultures of Mycobacteria-Sensitized Mice 
Hours PC Incu­ Source of PC Inhibition 
bated Before Myco­ Normal of EMCV 
Supernatant bacteria- Replication^ ̂  
Fluid Harvested Sensitized logl0 
(PFU/0.2 ml, log10) 
2 6.8 6.8 none 
4 6.3 6.8 0.5 
8 4.7 6.5 1.8 
12 4.8 6.8 2.0 
18 5.0 6.6 1.6 
24 4.7 6.8 2.1 
(a) Supernatant fluids were harvested from PC. of mycobacteria-
6 
sensitized and normal mice that were cultured at 5 x 10 
PC/ml. This is the sane concentration of PC that is normally 
incubated with infected monolayers. Following harvest, the 
fluids were centrifuged, mixed with an equal volume of MEM-2 
and subsequently overlaid on MEF monolayers that had been 
infected for 2 h with 5-7 PFU of EMCV. Eighteen hours later, 
the MEF cultures were harvested and titrated for virus. Cul­
tures incubated with MEM-2 alone had a titer of lO^*^ PFU/0.2 
ml, log1Q. 
(b) Inhibition of EMCV replication was determined by com­
paring viral titers in cultures of mycobacteria-sensitized 
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and normal mice that were incubated with supernatant fluids 
harvested at the same interval. 
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activity from other fluids of mycobacteria-sensitized mice. 
Serum from these mice diluted 1:5 in MEM as compared to 
serum at the same dilution from normal uninfected mice 
never inhibited viral replication (data not shown). Be­
cause mouse serum is toxic to monolayers higher concentra­
tions could not be used in the assay. Thus, in retrospect, 
antiviral activity may have been present in the sera, but 
it was too dilute to detect at the concentrations tested. 
Peritoneal washes from mycobacteria-sensitized and 
normal mice concentrated 10-to-20 fold were incubated with 
EMCV-infected MSF monolayers in another attempt to detect 
antiviral activity. No inhibition of viral replication 
was observed with these fluids (data not shown). 
Effect of supernatant fluid antiviral activity on EMCV 
titrations in ML cells. In the previous in vitro experi­
ments, entire cultures were harvested from EMCV-infected 
MEF monolayers after 18 h of incubation. Because PC sub­
sequently were shown to release an antiviral factor (see 
Table 12), it was considered that the mediator might possibly 
be influencing the EMCV titration assays even though titra-
- 3 tions were done at dilutions of 10 J and supernatant 
fluids usually were not active at dilutions 1:8. Further­
more, the mediator is inactive on the ML cells used for 
EMCV titrations (data not shown). Nonetheless, to be cer­
tain the mediator was not an influence, an experiment was 
designed in which entire cultures, washed monolayers only, 
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or supernatant fluids only were assayed. The data in 
Table 13 indicate that the mediator had no adverse effects 
on EMCV titrations in ML cellst replication was inhibited 
2»1 log10, 2.5 log10 and 2.2 log10 when entire cultures, 
washed monolayers only or fluids only were assayed. 
Continuous production of the antiviral mediator by PC 
of mycobacteria-sensitized mice. To determine the length 
of time the mediator was produced in culture, supernatant 
fluids were harvested after 24 h of incubation, the PC were 
washed, and then refed with fresh media; washing and re-
feeding was repeated 5 times at 24 h intervals. Without 
refeeding, supernatant fluids inhibited viral replication 
by 1.6 log^Q ( >90fo) \ interestingly, after one or two 
refeedings, inhibition increased markedly to 3-3 (^99.9#) 
and 2.6 log^Q ( >99%), respectively. Antiviral activity 
was still present but began to wane ( >90% inhibition) 
during the third refeeding and was not detected after the 
fourth of fifth (Table 14). 
Effect on EivlCV replication of supernatant fluids from 
PC cultures of mycobacteria-sensitized or normal mice incu­
bated with various concentrations of FCS. In an attempt 
to increase the antiviral activity of supernatant fluids, 
PC from mycobacteria-sensitized or normal mice were incubated 
in different concentrations of FCS. Increasing the amount 
of FCS up to 20# (a ten-fold increase over the usual 
TABLE 13 Effect of Supernatant Fluid Antiviral Activity on 
EMCV Titrations in ML Cells^3^ 
Portion of PC Source 
MEF Culture Myco- Normal None 
Assayed bacteria-
Sensitized 
Entire Culture 4.5 6.6 6.7 2.1 
MEF Cells only 3.6 6.1 6.2 2.5 
Culture fluid 
only 4.0 6.2 6.5 2.2 
(a) MEF monolayers that had been infected with 5-7 PFU of 
EMCV for 2 h were incubated with PC from mycobacteria-sensi­
tized or normal mice at a PC-to-MEF ratio of 20. After 18 h 
of incubation, entire cultures, washed monolayers only or 
media only were harvested and titrated for EMCV. 
(b) Inhibition of EMCV replication was determined by com­
paring viral titers in the same portions of cultures incu­
bated with PC of mycobacteria-sensitized or normal mice. 
Inhibition 
of EMCV 
Replication^ ̂ 
1°610 
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TABLE 14 Continuous Production of the Antiviral Mediator "by 
(a) 
PC of Mycobacteria-Sensitized Mice 
Number of Times Source of PC Inhibition 
Culture ! Refed Myco- Normal of EMCV 
at 24 h bacteria- D 1 • + * ( k ) Replication 
Intervals Sensitized l o Sl0  
(PFU/0.2 ml, iogio) 
NONE 4.8 6.4 1.6 
1 3.2 6.5 3.3 
2 3.2 5.8 2.6 
3 5.0 6.1  1 .1  
4  6.8 6.4 none 
5 7 .1  7 .0  none 
(a) Supernatant fluids of PC cultures from mycobacteria-
sensitized or normal mice at 5 x 10° PC/ml were harvested 
after 24 h of incubation and the PC then were washed and 
refed with the same amount of fresh MEM-2 as was removed. 
This process was repeated for 5 days. All fluids, at a 1:2 
dilution, were incubated on MEF monolayers that had been 
infected with 5-7 t'FU of EwCV for 2 h. Cultures were har­
vested at 18 h and titrated for virus. 
(b) Inhibition of EMCV replication was determined by com­
paring viral titers in cultures overlaid with supernatant 
fluids.from PC of mycobacteria-sensitized and normal mice 
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after the same number of refeedings. Monolayers incubated 
without supernatant fluids had a viral titer of 10K"^ PFU/ 
0.2 ml, log^Q. 
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concentration) did not improve the effectiveness of super­
natant fluids to inhibit EMCV replication (Table 15) • In 
fact, after additional dilution to 1»10, only fluids from 
PC incubated in 2$ FCS were positive (data not shown). 
Hereafter, all supernatant fluids were harvested from PC 
of mycobacteria-sensitized mice that were incubated in MEM-2. 
Effect of concentrated supernatant fluids from PC 
cultures of mycobacteria-sensitized and normal mice on 
EMCV replication. Supernatant fluids were concentrated 
under vacuum pressure in another attempt to enhance their 
antiviral activity. The data in Table 16 indicate that 
supernatant fluids concentrated 5-to-10 fold were more 
effective than unconcentrated fluids in the inhibition of 
EMCV replication. When supernatant fluids from PC cultures 
of mycobacteria-sensitized mice were concentrated 10-fold, 
inhibition of EMCV replication increased 0.5 log^Q, from 
1.7 L°§^O unconcentrated fluids) to 2.2 log^Q. Un­
fortunately, at the same concentration in which supernatant 
fluids showed increased antiviral activity,, they also 
became toxic, in that MEF monolayers usually died before the 
18 h assay was completed. Because the increased activity 
of the concentrated supernatant fluids may have been due 
to toxicity, and the antiviral effects were only marginal, 
this procedure was not continued. 
TABLE 15 Effect on EMCV Replication of Supernatant Fluids 
from PC Cultures of Mycobacteria-Sensitized or formal Mice 
( 3.) 
Incubated with Various Concentrations of FCS 
Concentration Source of P,C Inhibition 
of FCS Myco­ Normal of EMCV 
bacteria- Replication^) 
Sensitized iog10 
(PFU/0.2 ml, log10) 
20# 5-5 6.4 0.9 
10# 5.3 6.2 0.9 
2# 5.3 6.2 0.9 
(a) PC at1 5 x 10^ PC/ml, from mycobacteria-sensitized and 
normal mice, were incubated for 18 h in MEM with various 
concentrations of FCS. The fluids were diluted 1:2 in 
MEM containing different concentrations of FCS so that the 
final concentration of FCS in all media was 10#. Monolayers 
which had been infected for 2 h with 5-7 PFU of EMCV were 
subsequently overlaid with the fluids and 18 h later, entire 
cultures were harvested and titrated for EMCV. 
(b) Viral inhibition was determined by comparing the virus 
titers incubated with supernatant fluids from PC cultures of 
mycobacteria-sensitized and normal mice that had been grown 
in the same concentration of FCS. Cultures incubated without 
supernatant fluids had a viral titer of 10^PFU/0.2 ml, 
TABLE 16 Effects of Concentrated Supernatant Fluids from PC 
Cultures of Mycobacteria-Sensitized and Normal Mice on EMCV 
(a) 
Replication 
Concentration 
of Supernatant 
Fluid 
PC Source 
Myco­
bacteria-
Sensitized 
Normal 
(PFU/0.2 ml, log^) 
Inhibition 
of EMCV 
Replication 
(b) 
(log10) 
none 5.0 6.7 1.7 
5X 5.1 < 7.0 1.9 
10X 4.3 6.5 2.2 
(a) Eighteen hour supernatant fluids of PC cultures from 
mycobacteria-sensitized or normal mice were used unconcen-
trated or were concentrated in dialysis tubing under vacuum 
pressure at 4°C before incubation on MEF monolayers that 
had been infected with 5-7 PFU of EMCV for 2 h. After 18 h 
incubation, cultures were harvested and titrated for virus. 
(b) Inhibition of EMCV replication was determined by com­
paring virus titers in cultures overlaid with similiarly 
concentrated supernatant fluids from PC cultures of myco­
bacteria-sensitized and normal mice. Monolayers without 
supernatant fluids had a titer of 106*7 PFU/0.2 ml, log1Q. 
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Effect on EMCV replication of supernatant fluids from 
PC cultures of mycobacteria-sensitized or normal mice that 
were stimulated with PPD or OT. The mycobacterial antigens 
PPD or OT were added to PC cultures from mycobacteria-
sensitized or normal mice or to media only and the super­
natant fluids were harvested 18 h later. The data in 
Table 17 indicate that supernatant fluids from stimulated 
PC cultures of mycobacteria-sensitized mice had enhanced 
antiviral activity as compared to fluids harvested from 
PC of the same mice that had not been stimulated. Stimu­
lated PC from mycobacteria-sensitized mice released media­
tors which inhibited EMCV replication 1.5-1.7 a 
1:2 dilution; these fluids were still active at a 1:128 
dilution (data not shown). In contrast, the same PC that 
were not stimulated released mediators which inhibited 
EMCV replication by only 0.6 log10 at a 1:2 dilution; this 
activity could only be diluted to 1:8. The addition of 
PPD or OT to PC cultures of normal mice did not elicit 
release of an antiviral mediator. Similiarly, the antigens 
alone had no effect on viral replication if they were in­
cubated with the MEF used in the antiviral assay (Table 17). 
Interferon activity in supernatant fluids from PC 
cultures of mycobacteria-sensitized mice. To determine 
if the antiviral activity in supernatant fluids was inter­
feron, active supernatant fluids were incubated on unin­
fected MEF monolayers for 24 h, the monolayers were washed, 
TABLE 17 Effect on EMCV Replication of Supernatant Fluids 
from FC Cultures of Mycobacteria-Sensitized or Normal Mice 
that were Stimulated with PPD or 0T^a^ 
Antigen PC Source Inhibition 
Added to Myco- Normal None of EMCV 
PC Culture bacteria- Replication^ 
Sensitized 
(PFU/0.2 ml, log10) (logi0) 
50 ug OT 5.5 7.0 7.0 1.5 
100 ug PPD 4.8 6.5 6.3 1.7 
none 5*8 6.4 6.5 0.6 
(a) 50 u§ °f OT or 100 ug of PPD wore added to i;C cultures 
of mycobacteria-sensitized or normal mice at 5 x 106 PC/ml 
or to media alone. After an 18 h incubation the supernatant 
fluids were harvested and tested on MEF monolayers which 
had been infected with 5-7 PPU of EMCV for 2 h. Viral titers 
were determined 18 h later. 
(b) Inhibition of viral replication was determined by com­
paring viral titers in cultures overlaid with supernatant 
fluids from PC cultures of mycobacteria-sensitized or normal 
mice incubated with similiar amounts of PPD or OT. 
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challenged with VSV or EMCV and plaques counted; if plaque 
formation was inhibited > 50%, interferon was present. 
The data in Table 18 indicate that an interferon-like 
mediator was present in the supernatant fluids from PC 
cultures of mycobacteria-sensitized mice. Further char­
acterization of the mediator (Table 18) suggests that the 
interferon differed from both type I and type II mouse 
interferonsi it was labile to both pH 2 for 24 h at 4°G and 
heat at 56°C for 30 min, yet inhibited EMCV, VSV, HSV and 
VV replication) was nondialyzable, sensitive to trypsin 
(1.25 mg/ml) for 5 h at 37°C»and did not sediment after 
centrifugation at 100,000 x g for 1 h. In addition, it 
resembled a type II interferon because neither type II 
interferon nor the supernatant fluid interferon inhibited 
viral replication in GPK cells, whereas, type I interferon 
was active in these monolayers. Additional characterization 
of the interferon in supernatant fluids of PC cultures 
from mycobacteria-sensitized mice was done by incubating it 
with uninfected monolayers for various lengths of time 
and then challenging the monolayers with EMCV. The results 
in Table 19 indicate that when similiar units of interferon 
were tested, type I interferon protected monolayers when 
added 2 h prior to viral challenge, the type II interferon 
required 8 h, and the PC supernatant interferon 18 h. 
Because of these differences additional tests were done 
tb determine if the mediator in supernatant fluids was 
interferon and not virucidal or possibly anti-EMCV antibody. 
TABLE 18 Identification of the Antiviral Factor as Inter­
feron in Supernatant Fluids from PC Cultures of Mycobacteria-
( 3.) 
Sensitized Mice 
Treatment Type I Type II Unstimulated 
Interferon Interferon PC Interferon 
Stable at pH 2 for 24 h 
at 4°C + 
Stable at 56°C for 30 min - + 
Nondialyzable against PBS 
o •+• 
for 24 h at 4 C + 
Stable to trypsin for 5 h 
o 1 — 
at 37 C 
Sediments at 100,000 x g 
for 1 h 
Additional Characteristics 
+ + 
Inhibits EMCV or VSV in MEF + + 
+ + 
Inhibits RNA and DNA Viruses + 
Active in GPK cells + 
Minimum time (h) needed to 
inhibit virus in uninfected 
O 
monolayers 2 
Neutralized viruses 
Neutralized by anti-type I 
mouse interferon + 
Neutralized by anti-type II 
+ 
mouse interferon 
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18 
+ = yes 
- = no 
(a) All assays were performed with 2-6 units of interferon. 
The type I interferon was prepared by harvesting sera from mice 
2 h post-injection of 50 ug of poly (I)-poly (C); the type II 
interferon was prepared in mycobacteria-sensitized mice that 
were challenged i.v. with OT (see Materials and Methods). 
The unstimulated PC interferon was present in supernatant 
fluids from 18 h cultures of PC from mycobacteria-sensitized 
mice. 
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TABLE 19 Time Necessary to Detect Interferon Activity in Un-
( cl ) 
infected MEF Monolayers with Antiviral Substances 
Intervals (h) Antiviral Antiviral Substances 
Substance Incubated with Type I Type II Unstimulated 
MEF Monolayers Before Interferon Interferon PC Interferon 
Viral Challenge (# of Plaques) 
0 
1 
2 
4 
6 
8 
10 
1 2  
18  
20 
24 
29,27 
22,19 
11,9 * 
6,9 * 
(b) 
ND' 
5.4- * 
ND 
2,2 * 
ND 
ND 
1 , 1  *  
30,26 
27,28 
19,13 
23,16 
ND 
5,6 » 
ND 
4,2 * 
ND 
ND 
0 , 1  *  
15,27 
1 8 , 2 1  
15,27 
21,24 
1 8 , 1 8  
24,18 
21,30 
15 ,21  
3,6 * 
0,6 * 
0,3 * 
(a) 0.5 nil of each preparation diluted in MEiVI-2 to contain 
2 units of interferon was added to duplicate monolayers and 
at the times noted, the monolayers were washed and challenged 
with 20-30 PFU of EMCV. 24 h later, the number of plaques 
was reduced by > 50$ (#) from the number of plaques that were 
present in the virus control wells (0 h). 
(b) Not done 
72 
73 
The data in Table 20 indicate that the mediator present 
in active supernatant fluids did not neutralize or inac­
tivate EMCV even though the amount of time for the neutrali­
zation test was extended to cover the full length of the 
usual inhibition assay. The decreased plaque counts de­
tected at 18 and 24 h were probably due to the lability of 
EMCV because similiar decreases were noted when EMCV was 
incubated in media alone or with supernatant fluids pre­
pared from PC of mycobacteria-sensitized or normal mice. 
Additional experiments also determined that active super­
natant fluids did not interfere with EMCV adsorption and 
subsequent infection of MEF monolayers (data not shown). 
Thus, it was concluded that an interferon was present in 
supernatant fluids prepared from PC of mycobacteria-sensi­
tized mice. At. this time the interferon did not appear 
to be type I, but it was somewhat similiar although not 
identical to type II interferon. 
The differences between the type II interferon pro­
duced by unstimulated PC of mycobacteria-sensitized mice 
in this investigation and known classical type II interferons 
detected by others (44, 50, 53)» may tie due to the lack of 
stimulation of the PC by specific antigens; classical type 
II interferon is, by definition, produced by sensitized 
cells after specific antigenic restimulation (16, 18, 77). 
To determine if this was so, supernatant fluids were pre­
pared from PC cultures of mycobacteria-sensitized mice that, 
had been incubated with and without PPD. The supernatant 
TABLE 20 Neutralization Test Using Supernatant Fluids from 
(a) 
PC Cultures of Mycobacteria-Sensitized and Normal Mice 
Time of Source of Supernatant Fluid 
Incubation Mycobacteria- Normal PC None 
(hours) Sensitized PC (MEM-2) 
(# of plaques) 
1 32,28 31,27 33,25 
2 23,26 22,31 26,24 
4 23,27 32,23 36,33 
8 15,22 16,16 16,18 
12 21,20 17,17 25,26 
18 15,10 8,14 13,12 
24 4,5 2,1 1,4 
(a) 0.3 m1 of the supernatant fluids or MEM-2 was incubated 
with 0.3 ml of EMCV (approximately 35 PFU) for varying inter­
vals at 37°C, Samples were then assayed for the ability of 
EMCV to form plaques on ML monolayers overlaid with netho-
cellulose. The active supernatant fluid from PC of mycobac­
teria-sensitized mice inhibited EMCV replication by > 1 log^Q 
in MEF monolayers in a standard antiviral assay. 
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fluids then were heated at 56°C for 30 min and assayed for 
interferon activity. It was determined that the interferons 
were similiar in that both were labile to heat, and were, 
in contrast, unlike the classical type II interferon control 
which was stable after similiar treatment (data not shown). 
Thus, it appeared that the differences between interferon 
in supernatant fluids and standard type II interferon were 
not attributed to the lack of antigenic stimulation in 
PC cultures from mycobacteria-sensitized mice. 
Anti-interferon assays. The data presented to date 
has alluded to the presence of a mediator similiar to type II 
interferon in supernatant fluids from PC cultures of myco-
bacteria-sensitized mice. To confirm the identity of this 
mediator neutralization assays were done with an active 
supernatant fluid and rabbit anti-type I and anti-type II 
mouse interferons. The data in Table 21 indicate that 
anti-type II interferon, and not anti-type I interferon, 
neutralized the antiviral activity present in supernatant 
fluids from PC cultures of mycobacteria-sensitized mice. 
Additional proof of this identification was shown by the 
data which indicated that the two anti-interferons did 
not cross react with the known type I and type II interferon 
controls. Thus a heat labile type II interferon was released 
by PC from mycobacteria-sensitized mice. Furthermore, it 
did not require antigenic stimulation for production but 
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required twice a s  much time to protect uninfected i . i f i F  
monolayers from viral challenge as classical type II 
interferon. 
TABLE 2.1 Effect of Antibody to House Type I and Type II In­
terferons on Antiviral Activity of Supernatant Fluids from 
(a) 
PC Cultures of Mycobacteria-Sensitized Mice 
Experimental Groups Plaque Counts 
(Average of "3 monolayers) 
Type I interferon + NRG^) 0 
Type I interferon + anti-type I 15 
Type I interferon + anti-type II 0 
Type II interferon + NRG 3 
Type II interferon + anti-type I 2 
Type II interferon + anti-type II 13 
Unstimulated PC interferon + NRG 5 
Unstimulated PC interferon + anti-type I 3 
Unstimulated PC interferon + anti-type II 12 
Controls 
Anti-type I + MEM-2 15 
Anti-type II + MEM-2 17 
NRG + MEM-2 16 
(a) Similiar units of antiviral activity were assayed against 
rabbit anti-type I and anti-type II mouse interferons (see 
Materials and Methods). A 50# reduction in plaques as com­
pared to control plaques constitutes interferon activity. 
(b) Normal rabbit globulin 
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DISCUSSION 
These studies have shown that PC from C$7BL/l0ScN. 
mice sensitized with nonviable mycobacteria in an oil drop­
let emulsion inhibit EMCV replication in MEF monolayers 
when used at a PC-to-MEF ratio of 20. PC from mice sensi­
tized i.p. or i.v. 2-6 weeks previously with 50-500 ug 
of M. tuberculosis were the most effective. A series of 
subsequent experiments indicated that CFW/R MEF monolayers 
incubated with PC at 37°C for 18 h with low multiplicities 
(5-7 PFU) of EMCV resulted in optimal inhibition of viral 
replication. 
The possibility that adverse tissue culture conditions 
may have affected EMCV replication also was investigated. 
It was determined that the pH of EMCV-infected cultures 
incubated with media alone or PC from mycobacteria-sensi­
tized or normal mice was not significantly different (pH 
7.2-7.4) even though viral titers in cultures incubated 
with PC from mycobacteria-sensitized mice were 2.2 log^Q 
less than cultures incubated with PC from normal mice. 
Furthermore, the addition of fresh media to EMCV-infected 
cultures incubated with PC from mycobacteria-sensitized 
mice did not markedly change the degree of viral inhibition. 
These data excluded the possibility that unfavorable culture 
conditions were responsible for the viral inhibition. 
The kinetic studies indicated that PC from mycobacteria-
sensitized mice had to be in contact with the infected MEF 
monolayers for 8-10 h to inhibit EMCV replication. Prior 
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to this time, EMCV replication was not affected. Because 
EMCV requires 6-8 h to replicate (17), it appeared that 
viral replication was altered after the first and subsequent 
cycles of viral growth. This data supports the previous 
hypothesis of Lodmell and Ewalt that viral replication was 
necessary before inhibition of replication could be demon­
strated (39). In addition, studies using a high MOI in­
dicated that inhibition of viral replication only occurred 
when small amounts of virus were used to infect the mono­
layers; if 100# of the monolayer cells were infected, no 
inhibition of replication was observed. Thus, PC from myco­
bacteria-sensitized mice appeared to be inhibiting the 
spread of EMCV to uninfected MEF cells which concurs with 
the previously mentioned hypothesis. Furthermore, studies 
with radiolabeled MEF cells indicated that this inhibition 
of viral spread by the PC was not due to cytotoxicity. 
Because a) an 8-10 h incubation period was necessary 
before viral inhibition could be detected, b) decreased 
EMCV titers were due to the inhibition of viral spread to 
uninfected cells and c) cytotoxicity of MEF monolayers was 
not detected, subsequent studies turned to the possibility 
that an antiviral mediator produced by the PC was respon­
sible for viral inhibition. It was determined that cell-
free supernatant fluids harvested from PC cultures of myco­
bacteria-sensitized mice inhibited viral replication. 
Supernatant fluids harvested from PC cultures 2 h after 
incubation were inactive whereas those harvested at 4 h 
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showed slight activity. Similiar fluids harvested 8-24 h 
after incubation markedly inhibited EMCV replication. 
This data correlated well with the previously mentioned PC 
kinetics data. By stimulating the PC in culture with myco­
bacterial antigens or concentrating the fluids under vacuum 
pressure, the antiviral activity of supernatant fluids could 
be enhanced. Furthermore, when supernatant fluids were 
removed from PC cultures of mycobacteria-sensitized mice 
and the cells were refed with fresh media at 24 h intervals, 
the PC were shown to produce the mediator for at least 
72 h. This result, in addition to the data which indicated 
that neither nonviable cells nor the media in which the 
PC were rendered nonviable inhibited viral replication, 
indicated that the mediator was continually being produced 
and was not preformed. Serum or peritoneal washes from 
mycobacteria-sensitized mice, however, did not contain 
detectable antiviral activity. Characterization of the 
antiviral mediator(s) in supernatant fluids from PC cultures 
of mycobacteria-sensitized mice indicated that an interferon 
was responsible for the inhibition of EMCV replication. 
This mediator was labile to trypsin, pH 2 for 24 h, and 
56°C for 30 min. In addition, it was nondialyzable, non-
cytotoxic to EMCV-infected MEF target cells, species, but 
not viral specific, was not virucidal and did not neutralize 
EMCV. Furthermore, a rabbit anti-type II mouse interferon 
neutralized its antiviral activity as well as the activity 
of two known type II interferons. In contrast, a rabbit 
Si 
anti-type I mouse interferon had no effect on the antiviral 
activity of supernatant fluids. Thus, a type II interferon 
appeared to be responsible for the inhibition of EMCV 
replication in MEF monolayers overlaid with FC or super­
natant fluids from PC of mycobacteria-sensitized mice. 
The type II interferon produced by PC from mycobacteria-
sensitized mice differed in several ways from classical 
type II mouse interferon. First of all, antigenic stimu­
lation of the sensitized cells was not necessary for its 
production even though similiar treatment did enhance the 
titer. By definition type II or immune interferon is pro­
duced by previously sensitized cells after the cells are 
stimulated by the antigens that were used for sensitization 
(13). However, there are a few reports in the literature 
which indicate that type II interferon can be released 
from cells without additional stimulation of the sensitized 
effector cells (21 , 37, 53) • In one such study, I\'euman and 
Sorg demonstrated immune interferon production by macrophages 
from spleen cell cultures of BCG-infected mice. In this 
study, the mice were reinfected with BCG prior to harvest 
of their spleens (53)- In the present investigation, how­
ever, the mice were sensitized with nonviable mycobacteria 
and never rechallenged prior to harvest of PC. Morahan 
et al. also have shown that adherent PC from mice injected 
with Corynebacterium parvum or Corynebacterium acnes in­
hibited replication of several viruses in vitro without 
restimulation with corynebacterial antigens (37). Interferon 
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was postulated by these authors to be the mode of inhibition, 
but definite proof was not cited. In addition, Hirt et al. 
reported the production of immune interferon by unstimulated 
spleen cells from C. parvum-sensitized mice and in some 
cases, from normal spleen cells after prolonged incubation (26). 
In the system described herein, immune interferon 
was produced in the apparent absence of antigenic stimu­
lation; yet mycobacterial antigens could have been present 
in phagocytic cells within the PC population. Studies 
conducted to determine the effector cell(s) in this system, 
however, have shown that the cell is adherent but does not 
phagocytize carbonyl iron, and PC depleted of esterase 
positive and phagocytic cells produce an antiviral mediator 
(Cent, et al., manuscript in preparation). In addition, PC from 
i.v. injected mice inhibit EMCV replication and produced immune 
interferon and attempts to visualize mycobacteria in the PC 
by conventional staining techniques were unsuccessful (data 
not shown). Therefore, immune interferon apparently is 
released from mycobacteria-sensitized PC without additional 
stimulation. 
Another characteristic of the type II interferon re­
leased from PC of mycobacteria-sensitized mice that was 
different from classical type II interferons was its lability 
to heat at 56°C for 30 min; standard type II interferon is 
identified as being heat stable for M h at 56°C (63). 
Because the type II interferon identified in these studies 
was produced without mycobacterial stimulation of sensitized 
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cells, it may have been that a different type II interferon 
was synthesized which could therefore account for its heat 
lability. However, when the type II interferon was produced 
with PPD or 01 stimulation, the heat lability was the same 
as the interferon that was present in unstimulated cultures. 
Interestingly, there is a report in the literature of a 
heat labile immune interferon (71). Virelizier et al. de­
tected such a mediator in mixed lymphocyte cultures which 
decreased in titer from 450 to 54 units after 20 min incu­
bation at 56°C (71). This mediator was identified as type II 
interferon because of its acid lability and antiviral 
behavior. The immune interferon detected in supernatant 
fluids from PC cultures of mycobacteria-sensitized mice 
also was different from standard type II interferon in the 
amount of time that was necessary for similiar units of 
interferon to be in contact with uninfected monolayers to 
protect them from viral challenge; type I interferon re­
quired 2 h, classical type II interferon 8 h, and the super­
natant fluid mediator needed 18 h. In addition, the ML 
cell line originally used in these studies could not be 
protected by the type II interferon present in supernatant 
fluids whereas type I interferons were effective (data not 
shown). Consequently, it initially was thought that the 
mechanism of viral inhibition was not due to interferon. 
However, subsequent studies showed that classical type II 
interferon did not protect these cells as well as ML cells 
that were obtained for comparative studies. It could only 
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be concluded that the initial ML cells were somehow differ­
ent from other ML cells, and they were no longer used in 
subsequent interferon assays. It would be interesting to 
determine what is different about these ML cells that makes 
them refractory to type II interferon. This information 
could possibly lend insight into how interferon protects 
cells. In addition, the different ML cells might be used 
to differentiate between type I and type II interferons. 
Interferons are considered to be heterogeneous mole­
cules and this variability could account for the differences 
between classical type II interferon and the interferon 
found in PC cultures from mycobacteria-sensitized mice (18). 
Molecular weights have been reported from 45,000 to 80,000 
for type II interferon (77). T-he heterogenicity of inter­
feron molecules has been studied by Maehara and co-workers 
in which differences in interferons were detected based 
on the cellular source and mode of induction (44). Recently 
Stewart ̂ t al. have described two distinct type I interferons 
(67), and. it would seem reasonable, therefore, that two or 
more type II interferons also exist. In fact, Youngner has 
proposed that interferons can be as heterogeneous as anti­
bodies even though they commonly are protein molecules which 
require host synthesis to inhibit DNA and RNA virus replica­
tion without neutralization of viral particles (77). 
The in vitro production of immune interferon in this 
study can be used to explain the previous in vivo protection 
results reported by Lodmell and Ewalt (39. 40). It was 
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determined that mice which were sensitized i.v. or i.p. 
with mycobacteria were resistant to i.p., i.v., i.m. and 
s.c. EMCV challenge, results which would suggest that a 
mediator was involved in protection (39). Virus was de­
tected in target organs 24 h earlier in unsensitized mice 
than mycobacteria-sensitized mice (39), but EMGY did repli­
cate in mycobacteria-sensitized mice because viremia was 
detected at 72 h post-challenge in mice that subsequently 
survived (40). EMCV, however, failed to infect the CHS 
which ultimately results in death (39). Therefore, inter­
feron which is able to protect uninfected cells as well as 
slow cell division and concurrently slow viral replication 
(23) could control an EMCV infection which usually would 
overwhelm the immune system. In addition, interferon is 
known to cause changes in cell membrane surfaces (13. 46) 
and this could alter the ability of EMCV to infect certain 
cells including those of the CNS. Whether immune interferon 
regulates other parameters of the immune response _in vivo 
in this system is still unclear. 
Interferons have many effects on the immune system 
as well as being antiviral mediators (77). Type I interferon 
has been shown to enhance specialized cell function (23) 
especially associated with the T cell (13); these include 
decreased cell division, synthesis of prostaglandins and T cell 
RNA methylase and abolishment of delayed hypersensitivity 
(DTH) reactions (13> 23). Immune type II interferon, on the 
other hand, has recently been postulated to be a major 
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mediator of cellular immunity (71). Sonnenfeld et al. have 
described immune interferon to be 100 to 1000 times more 
effective as an antiviral or regulatory molecule than type 
I interferon. In addition, type II interferon can be either 
immunosuppressive or immunopotentiative depending on the 
dose and time of application of interferon in relation to 
antigen (Sonnenfeld, Mandel, and Merigan, personal communi­
cation, 77). Thus, it was concluded that the biological 
roles of type II interferon may be both immunoregulatory and 
antiviral (77). 
Type II interferon was first detected by vVheelock in 
1965 (72) and was described as immune interferon by Falcoff 
(16). Many studies have been conducted since that time 
to examine its role in cellular immunity, however, the pre­
cise mechanisms by which type II interferon functions within 
the immune system are still relatively unknown (71). 
Virelizier found that type II interferon protected glass-
adherent PC cultures from influenza virus and a highly 
virulent strain of mouse hepatitis virus which normally 
replicate in macrophages (71). Macrophages also have been 
associated with type I interferon by Manijias et al. in that 
their phagocytic ability was enhanced by its presence (45). 
A similiar situation was described by Huang e_t al. who 
showed an increased phagocytosis of colloidal carbon particles 
by mononuclear cells that had been pretreated with type I 
interferon (27). It would appear, therefore, that type II 
interferon also might effect macrophage function in a 
87 
similiar manner. Nonetheless, Lodmell has shown that EMCV 
was not adsorbed by cells in the plastic adherent cell 
populations of PC from mycobacteria-sensitized mice (Pusateri, 
et al..manuscript accepted for publication). In addition, pre­
vious in vivo work has demonstrated that rapid elimination 
of infectious EMCV by phagocytic cells from the sera of 
normal or mycobacteria-sensitized animals did not differ 
from 1-120 min after i.v. EMCV challenge (40). Thus, it 
would appear that enhanced phagocytosis as a result of 
interferon activity can be eliminated as a possible mechanism 
for the inhibition of EftCV replication in the in vitro and 
in vivo studies. 
I 
In several instances, interferon has been associated 
with the enhanced cellular cytotoxicity of viral-infected 
and tumor cells by T cells, NK cells and K cells (14, 37, 60, 
62). In a study by Lindahl et al. it was demonstrated that 
pre-treatment of sensitized lymphocytes for 6 h with 
interferon significantly enhanced their cytotoxic activity 
against allogenic tumor target cells (37). This enhancement 
was dose dependent and purified preparations of interferon 
were more effective than crude preparations (37). Similiarly, 
Djeu ejt al. noted that i.p. injected interferon or interferon 
inducers such as poly (I)-poly (C) could augment splenic iNK 
cell activity against leukemia target cells. This increase 
in cytotoxicity also could be demonstrated in normal spleen 
cell cultures after incubation for 18 h with interferon 
inducers; anti-interferon destroyed the enhanced cytotoxicity 
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both in vivo and in vitro (14). Santoli also noted increased 
NK cell activity against influenza-infected cells 6-24 h 
after treatment of the effector cells with interferon (60). 
In the majority of these studies, type I interferon was 
used, but again, there is no reason not to speculate that 
type II interferon could be operative in a similiar capacity. 
For example, Simon et al. detected two killer cell helper 
factors (KHF) in con A stimulated spleen cultures which 
enhanced killer (K) cell activity (62). One factor was 
closely associated with, or identical to, immune interferon 
in that the factor(s) could not be disassociated by pH 
sensitivity or molecular weight separation techniques and 
appeared to enhance the cytotoxicity of K cells by mechanisms 
independent of the second factor (62). Nonetheless, cyto­
toxicity experiments done in this investigation with PC 
from mycobacteria-sensitized mice indicated that neither 
the PC nor the antiviral supernatant fluids were cytotoxic, 
to EMCV-infected or uninfected MEF target cells. An in­
creased amount of -^Cr was released from monolayers incubated 
with PC from normal mice or media alone, but this increase 
was associated with cytopathy consequent to increased viral 
replication. Thus, cytotoxicity associated with enhanced 
NK cell, T cell or K cell activity by immune interferon 
does not appear to be a mechanism of inhibition by PC from 
mycobacteria-sensitized mice. Additional evidence which 
indicated that the NK cell was not important in the inhibition 
of EMCV replication has been shown by Wolfe et al. (74) who 
demonstrated that the NK cell was labile after incubation 
at 37°C for 8 h. Temperature experiments in this investi­
gation with PC from mycobacteria-sensitized mice had shown 
that the greatest inhibition of viral replication was de­
tected at 37°C. Furthermore, the kinetic studies indicated 
that no significant inhibition of virus replication by PC 
occurred before 8 h of incubation. Killer (K) cells, which 
require specific antibody to function (41), also can be 
discounted in this system because previous in vivo work 
indicated that 50% of the mycobacteria-sensitized mice which, 
survived EMCV challenge did not have serum EMCV Ab (39). 
In addition, in vitro data indicated that supernatant 
fluids from PC cultures of mycobacteria-sensitized mice 
did not neutralize EMCV. 
Mechanisms for inhibition of viral replication also 
did not appear to involve the functionally mature T lympho­
cyte. PC at a PC-to-MEF ratio of 20 from athymic nude mice 
sensitized with mycobacteria inhibited EMCV replication 
in vitro more effectively than PC from their similiarly 
sensitized nu/+ euthymic littermates or C57BL/l0ScN mice. 
In addition, PC from sensitized nude mice, but not the 
euthymic mice, inhibited EMCV replication at PC-to-MEF ratios 
2 and 1 (Lodmell et. al. , manuscript accepted for publication). 
Recently, however, Wietzerbin et al. have reported that 
athymic nude spleen cells stimulated with phytohemagglutinin 
(FHA) did produce immune interferon (73). A minor theta-
bearing cell population appeared to be the effector cell 
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although co-operation with other cells was required for the 
interferon production (73)- Nonetheless, studies with PC 
from mycobacteria-sensitized mice have shown that the ef­
fector cells adhered to nylon wool columns which is further 
evidence against T cell involvement (Cent jet al. ,manuscript in 
preparation). This data brings up an interesting,; point in that 
many investigators have stated that sensitized T cells were 
primarily responsible for production of classical immune 
interferon (13» 53» 73)- Perhaps the variable properties 
of the immune interferon detected in these studies can be 
explained because it was produced by cell populations in­
dependent of the T cell. 
Additional mediators of cellular immunity that have 
been detected in other studies could be partially responsible 
for EMCV inhibition because they have been closely associated 
with or unseparable from immune interferon (4, 50, 62, 75)• 
One study was described by Youngner et al. in which similiar-
ities in antigenic, biological and physical properties 
were noted between migration inhibitory factor (MIF) and 
immune interferon in sera of BCG-infected mice rechallenged 
with OT or live BCG (75)• For example, maximum production 
of the two mediators occurred at 2-3 weeks after infection 
in BCG-sensitized mice and inoculation of specific antigen 
that resulted in delayed hypersensitivity reactions. The 
peak activities of the two molecules corresponded to a 
molecular weight of 45,000 to 80,000 and both substances 
were sensitive to pH 2 (75)- In subsequent studies, Youngner 
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showed that immune interferon and the high titered MIF 
activity were produced by a heterogeneous cell population 
of T and B lymphocytes, whereas type I interferon with low 
titered MIF activity was produced by separate cell popula­
tions (76). Differentiation of the properties of MIF and 
immune interferon proved difficult and still has not been 
resolved (76). More recently, antiviral mediators have 
been detected from nonstimulated tissue culture cells in­
cluding secondary MEF cells (4, 28). These cell-produced 
viral inhibitors (CVI) were neither viral nor species 
specific, were sensitive to trypsin and appeared to inhibit 
viral attachment and penetration into the target cells. 
It is possible that the in vitro inhibition of viral repli­
cation in MEF monolayers in the studies reported herein 
may have been in part due to CVI. 
Even though interferons have been shown to have varied 
effects on the immune system, their antiviral effects are 
beyond reproach; on a molar basis, interferons are some of 
the most potent biological molecules known (18). Several 
investigators over the course of many years have tried to 
resolve the means by which they protect cells against 
viral infection (18). There are various mechanisms that 
have been proposed and the results appear to differ depending 
on the viral system that is studied (48). Many substances 
can induce interferon synthesis and some of the most 
effective are double-stranded RNA's; they are so 
effective that some investigators have proposed that all 
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inducers work by causing the production of double-stranded 
RNA (46). Regardless of the mode of induction, it is fairly 
well established that derepression of the interferon gene 
is the event that initiates interferon production. The in­
terferon molecules then diffuse to neighboring cells and bind 
to their surfaces; this binding initiates the synthesis of at. 
least three cellular proteins (46). The proteins are in­
active until the cells in which they are produced are in­
fected with a virus or exposed to double-stranded RNA. This 
requirement for activation protects cellular metabolism from 
the inhibitory effects of the proteins. The first of these 
molecules is a protein kinase, which in the presence of 
double-stranded RNA and ATP,1 transfers a phosphate group to 
an initiating factor needed for viral protein synthesis. 
This phosphorylation inactivates the viral initiation factor 
and thus, blocks viral protein synthesis. The second cellular 
protein catalyzes the formation of a nuclease activator from 
ATP which then activates the third cellular protein, an endo-
nuclease which breaks down viral mRNA molecules before they 
can direct synthesis of viral protein (46). There has been 
contradicting evidence on whether viral mRNA is more sensi­
tive to the actions of interferon than cellular RNA and the 
issue still has not been resolved. Nonetheless, there are 
at least two pathways by which viral inactivation can occur 
as a result of interferon production; one is at the initia­
tion of viral protein synthesis and the other at mRNA 
translation. Interferon also has been shown, by a different 
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mechanism, to affect the ability of some RNA tumor viruses 
to spread to uninfected cells. The synthesis of these 
viruses is not affected by the three cellular proteins 
described previously because the RNA viral genome is trans­
lated into DNA, incorporated into the cellular DNA and 
replicated along with the cellular genome. Friedman has 
found, however, that the virions are impaired from budding 
out of infected cells and has speculated that cellular 
membrane changes, caused by interferon pre-treatment, in­
hibited viral spread (46). These changes in the interferon-
treated cellular membrane have not been well characterized. 
In the model system of nonspecific immunity reported 
herein, the production of immune type II interferon has 
been detected in PC cultures from mycobacteria-sensitized 
mice and it is proposed that this antiviral molecule was 
responsible for the inhibition of EMCV replication. Al­
though antigenic stimulation of the PC was not necessary 
for the release of interferon, the addition of mycobacterial 
antigens such as PPD or OT enhanced its titer. This anti­
viral molecule did not appear to be preformed because non­
viable PC were ineffective. In addition, an 8-10 h incuba­
tion period was necessary to detect viral inhibition with 
FC from mycobacteria-sensitized mice on infected MEF and a 
similiar amount of time was necessary for PC cultures to 
release sufficient concentrations of interferon to signifi­
cantly inhibit EMCV replication. Several differences were 
noted between the immune interferon detected in these studies 
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and classical type II interferon. Included were heat labil­
ity and the requirement that over twice the amount of time 
was needed to protect uninfected monolayers against viral 
challenge with similiar units of interferon (18 h vs. 8 h 
for standard type II interferon). However, there were many 
similiarities between these two antiviral substances in that 
both acted by inhibiting viral spread to uninfected monolayer 
cells, and they were neither cytotoxic nor able to neutralize 
EMCV. In addition, both molecules were acid labile, trypsin-
sensitive (an indication that the active portion of the 
molecules was protein), and both inhibited the replication 
of several RNA and DNA viruses, but only in mouse cells. 
Lastly, the interferon present in supernatant fluids from 
PC cultures of mycobacteria-sensitized mice as well as 
standard type II interferons were neutralized by rabbit 
anti-mouse type II interferon. Further studies with this 
system of nonspecific immunity could include 1) a more 
detailed biochemical analysis of the differences between 
classical immune interferon and the type II interferon de­
tected in supernatant fluids, 2) a thorough study of the 
difference(s) in the ML cells initially used in this study 
which rendered them insensitive to type II interferon treat­
ment and 3) the regulation of the immune response _in vivo 
that is a result of type II interferon production. 
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